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ABSTRACT 
 
Henry, Ryan Edward (Ph.D., Molecular, Cellular and Developmental Biology) 
Novel Molecular Mechanisms that Modulate the Cellular Response to p53 Activation 
Thesis directed by Associate Professor Joaquín M. Espinosa 
 
 The p53 tumor suppressor protein is the most frequently mutated gene in human 
tumors and is amongst the most intensely studied molecules in modern biology.  p53 
acts primarily as a stress-responsive transcription factor that directly regulates the 
expression of over one hundred target genes, the products of which mediate such tumor 
suppressive responses as cell cycle arrest, apoptosis, senescence and DNA damage 
repair.  It is well established that p53-dependent cellular stress responses can vary, 
depending on both the nature of the p53-activating stimulus as well as the cell type 
experiencing the stress; however, the molecular mechanisms that drive cells to adopt 
one p53-dependent cellular response over another in a context-specific manner remain 
largely elusive and are the subject of my dissertation research.    
 First, using an experimental design wherein cell cycle arrest or apoptosis is 
elicited in a single cell type using non-genotoxic or genotoxic p53 activation, 
respectively, I investigated potential mechanisms driving stimulus-specific cellular 
responses.  Combining gene expression studies with loss-of-function experiments, I 
discovered that the death receptor DR4 is a novel factor modulating p53-dependent cell 
fate choice.  I found that while DR4 protein is expressed in dying cells and is required 
for apoptosis, DR4 fails to accumulate in cells undergoing cell cycle arrest.  Lastly, my 
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studies reveal that stimulus-specific DR4 expression results, at least in part, from p53-
independent stabilization of the DR4 mRNA in cells undergoing apoptosis.  
 Second, in a screen to identify novel constituents of the p53 transcriptional 
network, I identified the miR-34a locus as the first known example of a microRNA under 
the direct transcriptional control of p53 whose expression is cell type-specific.  Mature 
miR-34a levels negatively correlate with the degree of p53-induced apoptosis across a 
range of cancer cell types, and functional studies in HCT116 cells revealed that miR-
34a functions in an anti-apoptotic manner in the context of non-genotoxic p53 activation.  
Lastly, my data suggest that cell-type specific processing defects in the miR-34a 
primary transcript may affect mature miR-34a levels and thus the cellular response to 
p53 activation.  
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CHAPTER I 
 
INTRODUCTION 
 
CANCER: A DISEASE OF ABNORMAL GENE ACTIVITY 
 When thought of in the simplest of terms, the most basic unit of life, the cell, is 
composed of the exact same elements as its surrounding inanimate environment; but, it 
is the precise and sophisticated arrangement of the atoms into molecules, molecules 
into organelles and organelles into cells that creates order out of chaos and gives all 
cells their distinctive properties.  More complex still is the careful arrangement of cells 
into tissues, tissues into organs and organs into systems that combine to form 
metazoan organisms.  And underlying all this complexity is, of course, the genome, 
which encodes all of the instructions needed to ensure that an organism develops 
properly and that homeostatic mechanisms function robustly, allowing the organism 
enough time to reach its reproductive age, generate progeny and perpetuate the 
species.   
 Tissue homeostasis is an essential process for all metazoans and involves two 
opposing processes: cellular proliferation and cell death.  Throughout development and 
during the lifespan of any multicellular organism, new cells must be made to replenish 
damaged ones, and damaged cells that cannot be salvaged must be done away with.  
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In any tissue, this is achieved by balancing the amount of cell proliferation with 
programmed cell death.  In the physiological setting, the net result of balancing these 
processes is the proper growth and maintenance of the various tissues; however, when 
cell proliferation and programmed cell death become deregulated and cell division 
becomes unchecked, a pathological situation known as tumorigenesis ensues. 
Tumorigenesis is driven by cumulative genetic mutations in genes belonging to two 
fundamentally different classes, oncogenes and tumor suppressor genes, which then 
become deregulated and fail to function properly.  If left alone, a benign tumor often 
goes on to gain additional properties, becoming larger and more invasive of the 
surrounding healthy tissue.  Eventually, a population of cells within the primary tumor 
acquires the ability to detach from their initial location and spread throughout the body, 
a process known as metastasis. Invasion and metastasis distinguish bona fide cancers 
from benign tumors.  
 The molecular processes by which a healthy cell leads to the growth of a tumor, 
and eventually cancer, are amongst the most studied topics in modern biology.  
Thousands upon thousands of scientists have committed their careers to understanding 
how tumors and cancers arise, and just as many have sought to find ways to selectively 
eliminate tumor cells from a suffering patient while sparing healthy cells.  Regardless of 
which battlefront a cancer researcher finds themselves on, the goal remains steadfast; 
to treat and cure cancers, we must have an exquisite understanding of the molecular 
mechanisms that drive tumor formation, maintenance and metastasis.  Of equal 
importance, we must also understand how the specific repertoire of mutations in a 
tumor interacts with the rest of the genome to dictate the tumoral response to treatment.  
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ONCOGENES AND TUMOR SUPPRESSOR GENES 
Oncogenes 
 A gene may be classified as an oncogene if a gain-of-function mutation in the 
original proto-oncogene promotes tumorigenesis. Proto-oncogenes may normally 
function to promote cell growth, division, survival, motility and invasion. Gain-of-function 
oncogenic mutations may be as simple as a point mutation (single base transitions and 
transversions), resulting in an amino acid substitution that significantly alters the activity 
of the gene product, as exemplified by the V600E mutation in the B-RAF oncogene 
prevalently found in melanoma (Thomas, 2006).  Some oncogenic lesions are more 
complex, however, and involve large chromosomal translocations.  Some translocations 
result in the fusion of two protein-coding regions to create a de novo oncogenic protein, 
as in the case of the Philadelphia chromosome, which is a translocation between 
chromosomes 9 and 22 that fuses the Bcr gene with the Abl proto-oncogene, 
generating a constitutively active Abl kinase that promotes the onset of chronic myeloid 
leukemia (CML) (Deininger et al, 2000).  Alternatively, a translocation can reposition a 
promoter element upstream of a proto-oncogene, leading to the deregulated 
transcription and subsequent overexpression of an otherwise wild-type proto-oncogene.  
A classic example of this type of mutation is the t(8;14) translocation which places the 
promoter for the immunoglobulin heavy chain locus directly upstream of the gene 
encoding the MYC transcription factor (Hamlyn & Rabbitts, 1983; Taub et al, 1982).  
MYC overexpression is common in many tumors and drives hyper-proliferation (Nilsson 
& Cleveland, 2003).   
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Tumor Suppressor Genes 
 Opposing the action of oncogenes is a second class of genes commonly mutated 
during tumorigenesis, the tumor suppressors.  Tumor suppressor genes play myriad 
roles in the cell, from blocking cell cycle progression and mediating DNA damage repair 
to promoting various forms of programmed cell death, such as apoptosis.  Accordingly, 
tumor suppressor genes may be defined as genes for which loss-of-function mutations 
promote tumorigenesis, and not unlike the mutations that activate oncogenes, 
chromosomal deletions/rearrangements and point mutations are the most common 
genetic lesions that inactivate tumor suppressor genes.  
The first tumor suppressor gene to be discovered was the retinoblastoma gene, 
RB1 (Friend et al, 1986), the product of which negatively regulates entry into the cell 
cycle by binding and inhibiting the E2F family of transcription factor (Chellappan et al, 
1991; Weinberg, 1995).  Another major tumor suppressor identified was the 
phosphatase and tensin homolog (PTEN) gene, a dual-specificity protein phosphatase 
that antagonizes pro-survival/pro-proliferation PI3 kinase signaling (e.g. AKT signaling) 
and is amongst the most frequently mutated genes in a broad range of human cancers 
(Cantley & Neel, 1999; Li et al, 1997; Myers et al, 1997; Steck et al, 1997).  The second 
tumor suppressor gene to be discovered, the transcription factor p53 (TP53), is now 
widely acknowledged as the most frequently mutated tumor suppressor gene in humans 
cancers and is the topic of my dissertation research. 
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THE p53 TUMOR SUPPRESSOR PROTEIN 
p53: a historical perspective 
 Beginning with its discovery in 1979, the p53 protein has had a fascinating 
history, from being misidentified as an oncogene for the first ten years following its initial 
isolation to becoming acknowledged as the most commonly mutated tumor suppressor 
gene in human tumors.  The p53 protein was first identified as a 53 kilo-Dalton (kDa), 
tumor-specific antigen by immunoprecipitation and electrophoretic resolution of 
[S35]methionine-labeled proteins derived from both chemically- and virally-induced 
murine tumors (DeLeo et al, 1979).  A single radio-labeled protein was present in tumor-
derived, but not normal fibroblast-derived, protein extracts and could be 
immunoprecipitated with antisera raised against the tumor-derived extracts, but not with 
normal mouse serum.  In light of the fact that the murine p53 gene was cloned four 
years after these initial findings (see below), the DeLeo and colleagues correctly 
predicted that the p53 kDa protein was likely encoded by an endogenous, rather than a 
viral, gene and that its apparent tumor-specific expression pattern likely resulted from 
mutation of either a regulatory locus or of the p53 coding region itself that could liberate 
the protein from an endogenous regulator.  
 Paralleling the work of DeLeo et al., another group simultaneously identified a 
tumor-specific protein of approximately 54 kDa that co-immunoprecipitated with Large T 
antigen of the SV40 virus from transformed murine and hamster cells (Linzer & Levine, 
1979).  Linzer and Levine similarly concluded that the 54 kDa protein was encoded by 
an endogenous, not a viral, gene and that infection of cells with SV40 virus either 
stimulated the synthesis or hindered the degradation of the 54 kDa protein; however, 
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the authors were unable to ascertain the role of the protein in viral infection or 
transformation. 
 Intense study of the p53 protein in the years immediately following its initial 
discovery elucidated several mysterious aspects of the p53 protein.  p53 was found to 
be a phosphoprotein (Meek & Eckhart, 1988; Samad et al, 1986) whose levels were 
regulated by both mRNA abundance as well as by protein turnover (Reich et al, 1983).  
Confirmation that p53 was in fact a nuclear-encoded cellular protein and not a viral gene 
product came when the murine p53 gene was isolated (Zakut-Houri et al, 1983). 
 A decade after p53 was discovered, mounting evidence called into question the 
designation of wild-type p53 as an oncogene.  Studies of allelic deletions in human 
cancers had revealed that the short arm of chromosome 17 (17p) is often deleted in 
colorectal, breast and lung cancers, and the p53 gene had been previously mapped to a 
region of chromosome 17p located within this commonly-deleted region (van Tuinen et 
al, 1987). Because allelic deletions often indicate that a tumor suppressor gene is 
located within the ablated region, Baker and colleagues sought to determine if it was the 
p53 locus that was commonly deleted in this region.  The authors found that indeed, 
loss of a single p53 allele was found in two colorectal tumors and that in both cases, the 
remaining allele harbored a single point mutation (A143V and R175H) that had been 
previously observed in murine p53 alleles thought to be oncogenic (Baker et al, 1989; 
van Tuinen et al, 1987). This evidence suggested that wild-type p53 may in fact be a 
tumor suppressor, not an oncogene, and that the p53 isolated from so many tumors 
was actually a mutant form.  In fact, there is a large body of literature demonstrating that 
a variety of p53 mutants promote oncogenesis by a diverse range of mechanisms 
  7  
(reviewed in (Brosh & Rotter, 2009; Goh et al, 2011; Solomon et al, 2011)).  Thus, 
mutations in TP53 lead to the loss of tumor suppressor function, and depending on the 
nature of the mutation, may even confer upon p53 de novo oncogenic properties. 
p53 is a DNA-binding transcription factor  
 The first cellular function assigned to the p53 protein was that of a DNA-binding 
transcription factor, and this function is by far the most studied aspect of p53 biology. 
The first studies to suggest that p53 might act as a transcription factor did so indirectly, 
finding that p53 localized to the nucleus and partially associated with chromatin in 
transformed murine cell lines, but remained in the cytosol of non-transformed fibroblasts 
(Deppert & Haug, 1986; Rotter et al, 1983).  Evidence that p53 could directly bind 
double-stranded as well as single-stranded DNA came from in vitro studies (Lane & 
Gannon, 1983; Steinmeyer & Deppert, 1988), and cotransfection of p53 with a reporter 
gene construct showed that p53 could increase expression of the reporter gene, but this 
was still indirect evidence (Luria & Horowitz, 1986).  More direct evidence that p53 was 
a transcriptional transactivator came from experiments that fused the N-terminal 73 
amino acids of p53 to the DNA binding domain of the yGAL4 yeast transcription factor.  
Expression of the yGAL4-p53 fusion protein in yeast demonstrated that the N-terminus 
of p53 possesses a transactivation domain (TAD) capable of activating transcription to 
the same extent as the viral protein, VP16 (Fields & Jang, 1990).  Please refer to Figure 
1.1 for a detailed schematic of the p53 protein, including its domains, post-translational 
modifications and protein interactors. 
 The finding that p53 can non-specifically bind DNA in vitro and that the p53 N-
terminus contains a functional transactivation domain precipitated the search for the 
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exact DNA sequence(s) that p53 binds to in vivo.  The idea that p53 may bind to 
specific DNA sequences was further supported by a study of fifteen different tumor-
derived p53 mutants, which found that all fifteen mutants bound less tightly to calf 
thymus DNA in vitro than did wild-type p53 (Kern et al, 1991a). To experimentally 
identify p53 DNA binding sites, Kern and colleagues immunoprecipitated p53 that had 
been pre-incubated with both randomly-cloned, as well as rationally-chosen, human 
DNA fragments and found that only two of the more than 1400 clones tested bound 
strongly to wild-type, but not to mutant, p53 (Kern et al, 1991b).  They identified the 33 
bp sequence, CCTTGCCTGGACTTGCCTGGCCTTGCCTTTTCT, as specifically 
binding to p53, and concluded that the G residues within each of the three TGCCT 
repeats were required for p53 binding.  
 Shortly thereafter, a second group used a technique called CASTing (Cyclic 
Amplification and Selection of Targets) to identify potential p53 binding sites (BS) 
(Wright et al, 1991). After six rounds of enriching and amplifying specific DNA 
oligonucleotide sequences originating from a much larger initial pool, they found that 
wild-type p53 preferentially bound to the palindromic sequence, 
GGACATGCCCGGGCATGTCC (Funk et al, 1992).  Importantly, the authors then 
cloned this sequence upstream of a reporter construct and found that it indeed 
facilitated p53-dependent transcription of the reporter gene.  Due to the palindromic 
nature of the BS, the authors predicted that p53 would likely bind to the site as a dimer 
of dimers, a prediction that has since been proven correct (Friedman et al, 1993; 
Kitayner et al, 2006; McLure & Lee, 1998). 
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 A more refined definition of the consensus p53 binding site soon followed these 
initial studies when a p53 binding site as consisting of two 10 bp sequences 
(RRRC(A/T)(T/A)GYYY; R= G/A, Y=C/T) separated by 0-13 base pairs of intervening  
sequence was identified (el-Deiry et al, 1992; Tokino et al, 1994).  Two sequences were 
subsequently identified from the mouse genome that were nearly identical to the p53 
binding site found in humans (GGACATGCCCGGGCAAGCCC and 
AGACATGCCCAGACATGTGT), although one had a single base pair mismatch (G) 
from the human sequence (Zauberman et al, 1993).  This degenerate p53 binding site 
has since been confirmed by genome-wide studies using Chromatin 
immunoprecipitation (ChIP) coupled with sequencing of paired-end ditags (ChIP-PET) 
(Wei et al, 2006), and ChIP coupled with next-generation deep sequencing (ChIP-seq) 
(Botcheva et al, 2011). 
Regulation of p53 activity 
 Because p53 activation can halt cell growth or trigger the death of a cell, p53 
activity is tightly regulated in order for a metazoan organism to develop and survive.  
Although transcriptional control of the p53 locus has been observed in certain contexts 
(Sun et al, 1995; Wang & El-Deiry, 2006), p53 protein expression is predominantly 
regulated at the level of protein stability, and this primary mode of regulation is widely 
conserved amongst most higher eukaryotes.  Central to the regulation of p53 protein 
levels is the E3 ubiquitin ligase MDM2.  MDM2 binds to the N-terminal and C-terminal 
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Figure 1.1 | p53 protein domains, post-translational modifications, and known 
protein interactors.  Shown in this schematic are the p53 protein domains from N- 
to C-terminus (the amino acid positions (in humans) encompassed by each domain 
are shown in parentheses below each domain name).  Nuclear Localization Signal 
(NLS), Nuclear Export Signal (NES), tetramerization domain (TET), C-terminal 
regulatory domain (REG).  Depicted above the domain map are the known post-
translational modifications made to p53, the amino acid residues that are modified, 
and the enzymes that deposit each modification.  Modifications: phosphorylation 
(red), acetylation (dark blue), ubiquitination (green), ADP-ribosylation (purple), 
Neddylation (yellow), methylation (light blue) and Sumoylation (orange).  Shown 
below the domain map are the proteins known to interact with p53.  Figure adapted 
from (Boehme & Blattner, 2009).   
368  Karen A Böhme and Christine Blattner
changing conditions. In this review we will summarize 
current knowledge on how these modi!cations control 
p53 protein stability and activity.
Control of p53 abundance
"e anti-proliferative activity of p53 necessitates a tight 
control. Part of this control is performed by maintain-
ing p53 protein levels low. If p53 activity is dispensable, 
the protein is very e#ciently targeted for degradation by 
cellular 26S proteasomes. In addition, translation of p53 
RNA is kept at a low level due to binding of the ribosomal 
protein L26 to the 5a untranslated region of the p53 RNA, 
which reduces translation e#ciency (Takagi et al., 2005). 
Cellular conditions that require p53 activity rescue the 
tumor suppressor from proteasomal degradation and 
attenuate the inhibitory e$ect of L26 (Maltzman and 
Czyzyk, 1984; Takagi et al., 2005; O!r-Rosenfeld et al., 
2008), resulting in a strong accumulation of he tumor 
suppressor protein.
Regulation of p53 stability by Mdm2
Degradation of p53 in cellular proteasomes requires prior 
polyubiquitination of the tumor suppressor protein, a 
reaction that is catalyzed by several ubiquitin ligases. 
Despite the identi!cation of additional ubiquitin ligases 
in more recent years, the oncoprotein Mdm2 appears to 
be the most important regulator of p53. "is has been 
demonstrated convincingly with mice where both mdm2 
alleles have been genetically deleted. "ese animals died 
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Figure 1. Schematic drawing of the p53 protein. !e p53 protein consists of several functional domains, which are all intensively subjected to 
post-translational modi"cations. Moreover, an increasing number of proteins has been identi"ed to interact with these individual domains of the 
tumor suppressor protein. NLS: nuclear localization signal; TET: tetramerization domain; NES: nuclear export signal; REG: regulatory domain. 
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regions of p53 and ubiquitinates p53 at multiple lysine residues, mostly in the C-terminal 
domain, thus leading to p53 proteosomal degradation (Haupt et al, 1997; Kubbutat et al, 
1997).  As a direct transcriptional target of p53, MDM2 is upregulated in response to 
elevated p53 levels; thus, p53 and MDM2 form a negative feedback loop to maintain 
p53 at low levels in unstressed cells.  In addition to targeting p53 protein for destruction, 
MDM2 further attenuates p53 activity by binding to the N-terminal transactivation 
domains and Nuclear Localization Signal (NLS) of p53, blocking the ability of p53 to 
recruit cofactors needed for target gene transcription and sequestering p53 in the 
cytosol, respectively.  Lastly, as a testament to just how critical MDM2 is to suppressing 
p53 activity, early mouse experiments found that MDM2-/- mice die as embryos, 
whereas MDM2-/-, p53-/- double-null mice are viable (Jones et al, 1995). 
 Although MDM2-mediated ubiquitination is recognized as the primary mechanism 
governing p53 protein levels, the MDM2-related protein MDM4 (MDMX) is also a major 
regulator of p53 activity and is overexpressed in several cancers. Similarly to MDM2, 
MDM4 also binds the transactivation domains of p53, hindering the ability of p53 to 
regulate its transcriptional target genes (Riemenschneider et al, 1999).  Interestingly, 
although MDM4 contains a RING (Really Interesting New Gene) finger domain 
characteristic of several enzymes in the ubiquitination pathway, MDM4 does not serve 
as an E3 ubiquitin ligase for p53 nor does it export p53 from the nucleus (Jackson & 
Berberich, 2000; Stad et al, 2000).  In spite of the fact that MDM4 does not target p53 
for degradation by the proteosome, mouse experiments revealed that MDM4 deletion is 
embryonically lethal but can be rescued by concomitant deletion of p53 (Parant et al, 
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2001). Thus, MDM4 is a second critical regulator of p53 activity and tumorigenesis that 
is not functionally redundant with MDM2. 
 
THE p53 TRANSCRIPTIONAL NETWORK OF TARGET GENES 
 Decades of research establishing p53 as a DNA-binding transcription factor has 
created a list of genes that are considered direct transcriptional targets of p53.  As 
research continues to implicate p53 in cellular processes beyond cell cycle arrest, 
apoptosis and senescence, so too grows the list of p53 target genes.  Recently, Riley 
and colleagues performed a comprehensive analysis of the p53 literature and published 
a master list of bona fide p53 target genes as well as their respective p53 response 
elements (p53 REs).  To be included on the list, the authors required that a gene strictly 
meet three out of four criteria, thereby paring the list down to those genes most likely to 
be biologically relevant p53 targets.  The first criterion was that the gene in question 
must contain a consensus p53 RE within or nearby the gene.  Second, RNA and protein 
levels for the gene must be induced or repressed by wild type p53, but not by mutant 
p53.  Third, when cloned into a reporter construct, the p53 RE must be able to regulate 
the reporter gene.  Lastly, genomic DNA containing the p53 RE should be 
immunoprecipitated by a p53 antibody using a chromatin immunoprecipitation (ChIP) 
protocol.  Alternatively, if a p53 RE can be shifted in a gel shift (EMSA) assay by a p53 
antibody, this would also satisfy the fourth criterion.  Based on these criteria, the ‘official’ 
list contains 129 p53-responsive genes and 160 p53 REs, clearly indicating that some 
p53 target genes are regulated by more than one p53 RE (Riley et al, 2008).   
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Figure 1.2 | p53 transcriptional target genes regulate a wide variety of 
biological processes.  Although cell cycle arrest and apoptosis were amongst the 
first known p53-regulated stress responses, p53 has since been shown to regulate a 
wide variety of processes.  Shown in blue-grey text are examples of well-
characterized p53-regulated genes that mediate the corresponding biological process 
shown on the right.  Explanation of full gene names and official gene symbols 
(italicized): PUMA (p53 up-regulated modulator of apoptosis, BBC3), DRAM (DNA 
damage-regulated autophagy modulator protein 1, DRAM1), p21 (cyclin-dependent 
kinase inhibitor 1A, CDKN1A), R2 (ribonucleotide reductase M2 B (TP53 inducible), 
RRM2B), LIF (leukemia inhibitory factor, LIF), TSP1 (thrombospondin 1, THBS1), 
TIGAR (TP53-induced glycolysis and apoptosis regulator, C12orf5), ICAM-1 
(intercellular adhesion molecule 1, ICAM1), SCO2 (SCO cytochrome oxidase 
deficient homolog 2, SCO2), MDM2 (Mdm2 p53 binding protein homolog (mouse), 
MDM2), PAI-1 (serpin peptidase inhibitor, clade E, SERPINE1).  Figure modified and 
adapted from (Vousden & Prives, 2009) 
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 An unfortunate consequence of the second criterion, however, is that non-protein 
coding genes do not make the list.  At the time this list was published in 2008, there 
were no reports of p53 target genes that were not protein coding; however, that 
changed when I and several other groups discovered three microRNA loci (miR-34a, 
miR-34b and miR-34c) that are now well accepted p53 target genes (Chang et al, 2007; 
He et al, 2007; Raver-Shapira et al, 2007; Tarasov et al, 2007).  Even more recent was 
the discovery of several Long intergenic non-coding RNAs (Linc-RNAs) regulated by 
p53, such as Linc-p21 (Huarte et al, 2010).  Undoubtedly, as our understanding of the 
genome grows and additional classes of genes are discovered, we will be forced to 
reevaluate the true definition of a p53 target gene. Via the vast network of target genes 
mentioned above, p53 is currently thought to regulate about ten different biological 
processes, the most studied of which are cell cycle arrest, apoptosis, senescence and 
DNA damage repair (Figure 1.2 and (Vousden & Prives, 2009)).  
 
p53 AND CELL CYCLE ARREST 
 The eukaryotic cell cycle consists of four main phases: the first growth phase 
(G1), the DNA replication phase (S), a second growth phase and preparation for cell 
division (G2) followed by mitosis (M), the process of DNA segregation and cell division.  
The decision of a cell to enter into and progress through the cell cycle is a highly 
regulated process, controlled predominantly by cyclin-dependent kinases (CDKs).  
CDKs are a family of serine-threonine kinases that regulate cell cycle progression by 
phosphorylating a large network of cell cycle regulatory proteins. CDK activities are 
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controlled by the binding of a second set of proteins, the cyclins, as well as activating 
and inactivating phosphorylation events (Figure 1.3 and (Morgan, 1995)). 
 During embryogenesis and fetal development, nearly all of the cells in the body 
are able to grow and divide, slowly differentiating into specialized tissues and organs 
that eventually cease to divide further.  As adults, the overwhelming majority of cells in 
the body are post-mitotic, having irreversibly withdrawn from the cell cycle.  Importantly, 
several pools of cells exist within our bodies (stem cell compartments) that retain the 
ability to undergo cell division in order to replenish damaged cells and provide new cells 
for growth.  Given that deregulated cell division is a hallmark of cancer, it is not 
surprising that a main function of p53 is to induce cell cycle arrest in cells receiving 
inappropriate signals to divide. 
Cell cycle regulation by p53 target genes: p21, 14-3-3σ  and beyond 
 Early on in the search for p53-transcriptional target genes, the Vogelstein lab 
discovered a human gene designated as WAF1, which was upregulated by p53 and 
whose overexpression suppressed growth of several human tumor lines (el-Deiry et al, 
1993).  Concurrently, the Elledge lab discovered that WAF1 encodes a CDK inhibitor 
(they called it p21 or CIP1), capable of binding and inactivating the cyclin-E:CDK2 
complex to arrest cells in G1 (Dulic et al, 1994; el-Deiry et al, 1994).  Other studies 
found p21 protein associated with all CDK complexes in non-transformed cells, 
suggesting p21 may function as a pan-CDK inhibitor (Figure 1.3 and (Xiong et al, 1993; 
Zhang et al, 1993)). 
 Another key mediator of p53-induced cell cycle arrest is 14-3-3σ, which 
sequesters the CDC25 phosphatase in the cytoplasm, preventing it from removing 
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inhibitory phosphates on CDK1, thereby inducing cell cycle arrest primarily in the G2/M 
transition of the cell cycle (Hermeking et al, 1997; Laronga et al, 2000). Other p53 
targets involved in cell cycle arrest are BTG2 (Duriez et al, 2004; Guardavaccaro et al, 
2000; Puisieux & Magaud, 1999; Rouault et al, 1996) and REPRIMO (Ohki et al, 2000), 
but their mechanisms of action have not been fully elucidated. 
  
p53 AND APOPTOSIS 
Programmed Cell Death  
 Cell death can be broadly divided into two categories, Programmed Cell Death  
(PCD) and necrosis.  The term ‘Programmed Cell Death’ is most appropriately used in 
reference to the genetically-programmed cell death that occurs with precise temporal 
and spatial control during organismal development; however, the term has since been 
expanded to include any mode of cell death whose execution is dependent upon one or 
more genetically-encoded factors.  Regardless of the definition, PCD is an essential 
process in metazoans and plays as many roles in normal physiology as it does in 
pathological situations (Rudin & Thompson, 1997). Necrosis, on the other hand, is a 
non-programmed, passive form of death. 
 For decades, PCD subtypes have been largely characterized and classified 
based on cell morphological features; however, this system has become antiquated as 
of late.  Recently, the Nomenclature Committee on Cell Death (NCCD) for 2012 
recommended that the different subroutines of PCD be classified based on very specific 
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Figure 1.3 | The eukaryotic cell cycle and its regulation by CDKs and CDK 
inhibitors.  Shown in colored arrows are the four main phases of the eukaryotic cell 
cycle: The first Gap phase (G1), the phase of DNA synthesis (S), a second Gap 
phase (G2) and lastly the phase in which the duplicated DNA is segregated into each 
of two daughter cells followed by cytokinesis (mitosis, M).  Note that toward the end 
of the G1 phase is located a checkpoint (restriction point, R) where the cell must 
make the decision to proceed into S phase or remain in G1.  Also depicted are the 
CDK:cyclin pairs that regulate  progression into/through each phase. Also shown are 
the major CDK inhibitors (CKIs) that inhibit the function of CDKs, typically by binding 
to the CDK subunit and blocking the interaction with its cognate cyclin.  CKIs are 
divided into two families based on their specificity for the various CDKs; see (Sherr & 
Roberts, 1999) for a review of CKIs.  The CIP/KIP family inhibits CDK2, 4 and 6, 
whereas the INK4 family inhbits CDK4 and 6 more specifically.  INK4, (inhibitor of 
CDK4).  CIP, (CDK-interacting protein).     Figure adapted from (Dehay & Kennedy, 
2007) 
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and quantifiable biochemical measurements rather than on cell morphological traits 
(Galluzzi et al, 2012).  Based on these revised criteria for defining cell death modalities, 
the Committee now recognizes as many as thirteen distinct types of PCD, including the 
three most studied forms; apoptosis (type I cell death), autophagy (type II cell death) 
and a programmed form of necrosis dubbed ‘necroptosis’ which has only recently been 
biochemically elucidated (Christofferson & Yuan, 2010).  My work described in Chapter 
2 is primarily a study of apoptosis, and how both p53-dependent and independent 
molecular events converge to affect cell fate choice following stimulus-specific p53 
activation. In the following sections, I will introduce the main mechanisms of vertebrate 
apoptosis, pointing out the myriad p53-regulated genes known to modulate the 
apoptotic response. 
 
Apoptosis: the beginning 
 Based on unconfirmed historical accounts, the word ‘apoptosis’ meaning ‘falling 
off’ was first used by Hippocrates in approximately 400 B.C. to describe the tissue that 
fell off of the bones of a patient with gangrene (Esposti, 1998); however, contemporary 
usage of term began in 1972 with a seminal paper by Kerr and colleagues in which they 
describe two distinct stages of ‘controlled cell deletion’. Using only microscopy-based 
methods, the authors demonstrated that the nuclear and cytoplasmic compartments in a 
cell undergoing apoptosis first shrink and break apart into smaller, membrane-enclosed 
bodies.  In a second step, the dying cell either detaches from its neighbors or is 
engulfed by surrounding cells, where the apoptotic debris is digested in a manner 
consistent with lysosomal degradation (Kerr et al, 1972).    
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 In the four decades since Kerr’s original accounts of apoptosis in animal cells, we 
now understand, in exquisite detail, many of the biochemical and molecular steps that 
initiate and carry out apoptosis.  Historically, apoptosis in vertebrate cells has been 
synonymous with two major cellular events, the activation of a family of cysteine 
proteases (caspases) and mitochondrial outer membrane permeabilization (MOMP).  
Generally speaking, one or both of these processes are required for apoptosis to 
proceed and each will be thoroughly introduced below in the following sections; 
however, based on recent suggestions by the 2012 NCCD, apoptosis has now been 
resolved into four subcategories: i) caspase-dependent intrinsic apoptosis, ii) caspase-
independent intrinsic apoptosis, iii) extrinsic apoptosis based on death receptors and iv) 
extrinsic apoptosis based on dependence receptors. Therefore, although perhaps a 
matter of semantics, the currently accepted definition of apoptosis in vertebrate cells is 
a form of programmed cell death requiring either the activation of caspases or the loss 
of mitochondrial outer membrane integrity.  
 
Caspases 
 The caspases are a family of endopeptidases that utilize an active site cysteine 
to cleave their target proteins after aspartic acid residues, hence the name (cysteine 
proteases that cleave proteins after aspartic acid residues).  Although caspases have 
been shown to function outside of apoptosis (Algeciras-Schimnich et al, 2002; Schwerk 
& Schulze-Osthoff, 2003), caspase activation has long been a hallmark of cells 
undergoing apoptosis.  In fact, before apoptosis was redefined to include caspase-
independent forms, the presence of caspase activity within a cell was synonymous with 
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a cell undergoing apoptosis.  Most vertebrate genomes encode multiple caspases.  
Excluding splice variants, the human genome encodes at least eleven distinct caspases 
(Figure 1.4).  The caspase family is broken down into initiator caspases and executioner 
caspases depending on where in the proteolytic cascade they function. In vertebrates, 
apoptosis is initiated via two distinct pathways.  One pathway is triggered by the 
formation of proteinaceous pores in the outer membrane of the mitochondrion and is 
referred to as the intrinsic apoptotic pathway, which activates the initiator caspase 9.  
The second apoptotic pathway is initiated at the cell surface by a family of receptors 
appropriately named ‘death receptors’ and is referred to as the extrinsic apoptotic 
pathway, which involves the initiator caspases 8 and 10.  Eventually, both pathways 
lead to activation of executioner caspases, such as caspases 3, 6 and 7. Although each 
pathway can be triggered independently of the other, both apoptotic pathways are often 
activated concomitantly, and in certain scenarios can regulate each other, as will be 
discussed below.  For ease of explanation, I will first describe each apoptotic pathway 
separately and conclude by discussing what is known about how both pathways interact 
with each other. 
 
The Intrinsic Apoptotic Pathway  
 Activation of the intrinsic apoptotic pathway is ultimately governed by the 
mitochondria.  The mitochondrion is a cellular organelle bound by a double lipid 
membrane. The innermost lumen, the mitochondrial matrix, is bounded by the inner 
mitochondrial membrane (IMM), which is separated from the mitochondrial outer 
membrane (MOM) by another lumen, the inter-membrane space, or IMS.  The first high-
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Figure 1.4 | Zymogen domain structures of vertebrate caspases.  Caspases are 
synthesized as inactive proenzymes (zymogens), with an N-terminal peptide or 
prodomain (PRO, light pink boxes), and two subunits that are often separated by a 
linker peptide (black box). Active caspases are heterotetramers composed of two 
large (grey boxes) and two small subunits (magenta boxes).  Proenzymes are 
activated via cleavage at the specific aspartic acid residues (DX, where X is the 
amino acid position in the protein). The number to the right of each caspase is the 
amino acid length of each proenzyme.  ‘FADD homology’ represents the domains of 
caspase-8 and caspase-10 that are homologous to the Death Effector Domain (DED) 
of the FADD adaptor protein.  Caspases 2, 8, 9 and 10 are regarded as initiator 
caspases (note: initiator caspases have relatively long prodomains).  Caspases 3, 6 
and 7 are executioner caspases and have relatively short prodomains.  Caspases 1, 
4 and 5 are involved in cytokine activation and the inflammatory response, and are 
not thought to play a significant role in the regulation of apoptosis (Fuentes-Prior & 
Salvesen, 2004).  Figure adapted from (Cohen, 1997). 
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Figure 3 Proenzyme organization of the caspases
Caspases are synthesized as proenzymes, with a N-terminal peptide or prodomain (PRO), and two subunits sometimes separated by a linker peptide (black box). Based on caspase-1 and caspase-
3, active enzymes are heterotetramers of two large (! 20 kDa ; p20) and two small (! 10 kDa ; p10) subunits. The proenzymes are cleaved at specific Asp residues (Dn, where n is the position
in the protein). The numbers at the right-hand side are the numbers of amino acids in the protein. aExact cleavage site not known ; bthe cleavage site of caspase-3 may be at Asp-9 or Asp-28
[65–67] ; ccaspase-9 is cleaved preferentially at Asp-330 by caspase-3 and at Asp-315 by granzyme B [82]. Caspase-2 cleavage sites are based on equivalent sites being present in Nedd2 [60,61].
FADD represents the domains of caspase-8 and caspase-10 that are homologous to the DED of FADD/MORT1.
synthesized as a model substrate, and Ac-DEVD.CHO and its
biotinylated derivatives were synthesized as specific inhibitors of
PARP cleav ge and as affinity lig nds fo purification of the
protease. Using electrospray MS and N-terminal sequence
analysis, the active enzyme was shown to be composed of two
subunits of 17 kDa and 12 kDa, derived from the precursor
protein by cl avage at Asp-28–Ser-29 and Asp-175–Ser-176 [65]
(Figure 3). While the initial cleavage is probably between the
large and small subunits, it has been suggested that processing
within the prodomain occurs initially at Asp-9, not at Asp-28
[66,67].
During the execution phase of apoptosis, caspase-3 is re-
sponsible either wholly or in part for the proteolysis of a large
number of substrates, each of which contains a common Asp-
Xaa-Xaa-Asp (DXXD) motif (Table 3), similar to that originally
described in PARP [68]. In comparison with caspase-1, caspase-
3 has no linker peptide and the prodomain is much shorter
(Figures 2b and 3). Caspase-3 prefers a DXXD-like substrate,
whereas caspase-1 pref r a YVAD-like substrate [65]. Both
enzymes have an almost absolute requirement for an Asp in the
P
!
position and both can tolerate a fair degree of substitution in
the P
"
and P
#
positions, but in the P
$
position caspase-1 prefers
a hydrophobic amin acid such as Tyr, whereas caspase-3 has a
marked preference for an Asp. The three-dimensional structure
of a complex of caspase-3 with DEVD.CHO, a potent tetra-
peptide aldehyde inhibitor, shows that, although caspase-3
resembles caspase-1 in overall structure, its S
$
subsite is very
different in size and chemical composition and accounts for their
differences in specificity [69]. The S
$
subsite of caspase-1 is a large
shallow hydrophobic depression that readily accommodates a
tyrosyl side chain, while the analogous site in caspase-3 is a
narrow pocket that closely surrounds the P
$
Asp side chain [69].
  22  
quality images of mitochondria obtained by electron microscopy (Palade, 1952) 
suggested that mitochondria were discrete, bean-like structures scattered throughout 
the cytoplasm.  Owing to vast improvements in imaging techniques, we now know 
mitochondria to be highly dynamic organelles that undergo both fusion and fission to 
create a large, interconnected syncytium within the cell rather than existing as smaller, 
distinct structures (Hoppins et al, 2007).  Mitochondria are perhaps best known as the 
‘powerhouses of the cell’ responsible for the majority of ATP production in most animal 
cell types; however, mitochondria also play a critical role in regulating apoptosis, not 
only in vertebrates but also in worms and flies, albeit by different mechanisms.   
 In vertebrate cells, the intrinsic apoptotic pathway triggers the caspase cascade 
by activating initiator caspase 9.  This activation is achieved via the formation of the 
apoptosome, a large protein complex consisting of the inactive pro-form of caspase 9, 
Apoptotic Peptidase Activating Factor 1 (APAF1) and the mitochondrial protein, 
cytochrome C (Figure 1.6).  Assembly of the apoptosome positions the caspase 9 
zymogens in such proximity that adjacent caspase 9 molecules proteolytically activate 
each other, a mode of activation referred to as ‘induced proximity’. Importantly, APAF1 
transcription is induced by p53 (Moroni et al, 2001).   
 Cytochrome C release from the mitochondria is a key regulatory step in the 
intrinsic pathway and requires the formation of protein pores in the MOM.  In 
vertebrates, it is well accepted that three pro-apoptotic members of the BCL2 protein 
family (BAX, BAK and BOK) form large homo-oligomeric pores facilitating the release of 
cytochrome C as well as several other pro-apoptotic proteins from the mitochondrial 
IMS. This process is known as ‘mitochondrial outer membrane permeabilization’ or 
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MOMP.   Of these three ‘pore’ proteins, BAX and BAK are the best characterized, likely 
owing to the fact that they are widely expressed throughout the body; furthermore, BAX 
is a well described p53-target gene in humans (Miyashita & Reed, 1995), but 
interestingly, is not known to be a direct p53-target gene in mice (Schmidt et al, 1999).  
BOK expression is more restricted, occurring mostly in reproductive tissues (Hsu et al, 
1997), and although p53-dependent BOK induction has been described, there is no 
evidence that this effect is direct (Yakovlev et al, 2004).  Given our relative dearth of 
knowledge with respect to BOK function and regulation, it will not be discussed further. 
 In healthy cells, BAX protein is mostly soluble and localizes to the cytosol, 
whereas BAK is constitutively targeted for insertion into the MOM (the mechanistic 
details of BAX translocation from the cytosol to the mitochondria will be discussed in 
detail in Chapters 3 and 4).  Once present in the MOM, pore formation by BAX and BAK 
is inhibited by a subset of BCL2 family members that bind directly to BAX and BAK, 
blocking their oligomerization into pores.  These anti-apoptotic BCL-2 proteins include 
BCL-2, BCL-XL, BCL-w, MCL-1 and Bfl-1.  Interestingly, p53 represses the BCL2 locus 
(Miyashita et al, 1994a), possibly by sterically interfering with a stronger transcription 
factor, POu4F1 (Budhram-Mahadeo et al, 1999).  In addition to directly repressing the 
oligomerization of the pro-apoptotic BCL2 proteins, the anti-apoptotic BCL-2 family 
members also directly bind and repress a third and final subset of BCL-2 family 
proteins, the ‘BH3-only’ proteins (refer to Figure 1.5 for a graphical summary of the 
BCL-2 protein family). 
 The ‘BH3-only’ proteins are so named because they contain only the third BH 
domain of a typical anti-apoptotic BCL-2 family protein, which has four BH domains 
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(BH1-4).  Of the three subsets of BCL-2 family proteins, the BH3-only group is the 
largest, consisting of PUMA, NOXA, BID, BAD, BIM, BIK, BMF and HKR/DP5.  Of these 
genes, p53 has been shown to directly upregulate the transcription of the PUMA 
(BBC3), NOXA (PMAIP1) and BID loci (Nakano & Vousden, 2001; Oda et al, 2000; Sax 
et al, 2002; Yu et al, 2001).  Increased expression of BH3-only proteins can lead to 
activation of the intrinsic apoptotic pathway by at least two mechanisms: inhibition of 
BCL-2 pro-survival factors and direct activation of BAX. The contribution of each 
mechanism in different scenarios is the subject of much debate in the field. 
 In summary, the relative balance between the pore forming proteins, anti-
apoptotic BCL2 proteins and BH3-only proteins ultimately determines whether or not 
conditions are right for the formation of MOM pores. p53 tips the balance toward MOMP 
by upregulating BH3-only proteins and BAX, and by repressing BCL-2. Furthermore, 
p53 ensures apoptosome formation by inducing APAF1. As discussed later, my thesis 
work has investigated the relative importance of these p53-dependent events to the 
cellular commitment to apoptosis. 
  
The Extrinsic Apoptotic Pathway 
 The second major branch of the vertebrate apoptotic pathway is the death 
receptor or extrinsic apoptotic pathway (Figure 1.6), so named because the death 
receptors that trigger the apoptotic cascade are activated when they engage a cognate 
death ligand in the extracellular space.  The prototypical death receptor protein has an 
extracellular ligand-binding domain, a single-pass transmembrane domain, and most 
contain an intracellular death domain (DD), which functions to recruit adaptor proteins 
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Figure 1.5 | The BCL-2 family of proteins.  BCL2 family members are divided into 
three subgroups based on their function and the specific complement of BCL2-
homology (BH) domains they contain.  Anti-apoptotic members contain all four BH 
domains, the pro-apoptotic members that form the mitochondrial pores contain BH1-
3 domains, and the aptly-named BH3-only proteins are also pro-apoptotic. TM, 
transmembrane domain.  Numbers to the right of each protein represents the 
molecular mass in kiloDaltons (kDa).  Note: BCL-B is also known as ‘Boo’ or ‘Diva’ 
(official gene name is BCL2L10), but little is known about its function relative to the 
other anti-apoptotic BCL-2 members.  Figure adapted from (Taylor et al, 2008). 
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that also contain a DD.  In the classic model of death receptor signaling, an extracellular 
death ligand recruits monomeric death receptor proteins into a trimer on the plasma 
membrane, a process that may occur within the context of a lipid raft in certain 
circumstances.  Upon trimerization, the intracellular DDs of the three death receptor 
molecules form a docking site to recruit DD-containing adaptor proteins.  Adaptor 
proteins in turn recruit the inactive (zymogen) form of the initiator caspase for the 
extrinsic pathway, caspase 8, via their Death Effector Domain (DED), a domain also 
present in the caspase 8 precursor.  This minimal complex comprised of death 
receptors, adaptor proteins and caspase 8 has been dubbed the Death Induced 
Signaling Complex (DISC).    
 Although the DISC is now known to include various additional proteins depending 
on the cellular context, the term is still widely used to refer to the caspase 8-activating 
complex formed at the plasma membrane by death receptors engaged by death 
ligands.  Analogous to the apoptosome that induces the cleavage of caspase 9 in the 
intrinsic pathway, the function of the DISC is to bring into close proximity the inactive 
caspase 8 precursor proteins such that adjacent caspase 8 molecules can 
proteolytically activate each other.  Once cleaved, caspase 8 egresses from the DISC to 
engage its target substrates, namely BID and caspase 3, although novel substrates of 
caspase 8 are still being discovered. 
 Death receptors belong to the Tumor Necrosis Factor Receptor (TNFR) 
superfamily of transmembrane receptors, which include TNFR1 (ligand: TNFα), TNFR2 
(ligand: TNFα), FAS (ligand: FASL), DR3 (ligand: TL1A), DR4 (ligand: TRAIL), DR5 
(ligand: TRAIL) and DR6 (ligand: tentatively, a cleavage fragment of the beta-amyloid 
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precursor protein, APP).  Additionally, three decoy receptors have been identified 
(DcR1, DcR2 and OPG) that compete with DR4 and DR5 for binding to TRAIL and 
attenuate pro-apoptotic signaling (Emery et al, 1998; Marsters et al, 1997; Sheridan et 
al, 1997).  
 The FAS, DR4 and DR5 receptors signal via the FAS-associated via death 
domain (FADD) adaptor protein, which in turn recruits caspase 8 to form the DISC; 
however, TNFR1 and DR3 must first recruit the TNFR1-associated death domain 
(TRADD) adaptor protein in order to bind FADD and caspase 8.  In contrast to these 
receptors, DR6 has been shown to signal apoptosis through TRADD, but not FADD 
(Kasof et al, 2001), and TNFR2, which lacks a death domain, has not been shown to 
recruit either FADD or TRADD, but instead signals through the TRAF family of adaptor 
proteins (Baud & Karin, 2001; Tewari & Dixit, 1996).  Importantly, p53 has been found to 
directly regulate the expression of several proteins involved in the extrinsic apoptotic 
pathway.  Of the six death receptors mentioned above, the FAS and DR5 loci are both 
well-characterized p53 target genes (Muller et al, 1998; Owen-Schaub et al, 1995; 
Takimoto & El-Deiry, 2000).  There is also evidence that the DR4 locus is directly 
upregulated by p53 (Guan et al, 2001; Liu et al, 2004b), but this has not been 
demonstrated as robustly as for FAS and DR5.  Lastly, p53 has been shown to directly 
regulate the expression of the decoy receptors DcR1 and DcR2 (Liu et al, 2005c). 
 
Crosstalk between the Intrinsic and Extrinsic Apoptotic Pathways 
 In certain experimental contexts, it has been shown that activation of either the 
intrinsic or extrinsic apoptotic pathway is sufficient to trigger apoptosis and kill a cell, but 
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under some conditions, both arms of the apoptotic pathway are required for efficient 
induction of apoptosis (Barnhart et al, 2003; Scaffidi et al, 1998; Srinivasula et al, 1996).  
Accordingly, there are two major ways in which the intrinsic and extrinsic pathways 
communicate to amplify the caspase cascade.  If the intrinsic pathway is engaged first, 
caspase 3 activated via caspase 9 can directly cleave and activate caspase 8.  
Activated caspase 8 can then cleave full-length BID into truncated BID (tBID), which is 
then competent to promote BAX/BAK oligomerization and increase MOMP.  Increased 
MOMP facilitates additional cytochrome C release into the mitochondria, which leads to 
more apoptosome formation and caspase 9 activation, thus amplifying caspase 3 
activation (Figure 1.6).   
 In cases where the death signal is initiated by the extrinsic pathway, caspase 8 
directly cleaves the executioner caspase 3 and apoptosis proceeds; however, in some 
cases, the amount of caspase 8 activation may not be enough to sufficiently activate 
caspase 3.  In these instances, caspase 8 can cleave BID into tBID, as mentioned 
above, which in turn promotes pore formation in the MOM and release of cytochrome C 
in order to trigger the activation of caspase 9, which then cleaves and activates caspase 
3.  Thus, caspase 8 communication with the mitochondria via BID cleavage provides a 
second avenue to executioner caspase 3 activation (Figure 1.6).  My thesis work 
illuminated the critical importance of this dialog between the two pathways in p53-
dependent apoptosis. 
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Figure 1.6 | Activation of the intrinsic and extrinsic apoptotic pathways and the 
important crosstalk mechanisms between the pathways.  Factors present in this 
diagram but not mentioned in the main text are IAPs (inhibitors of apoptosis), SMAC 
(second mitochondria-derived activator of caspase, DIABLO), and cFLIP (cellular 
FLICE-like inhibitory protein, CFLAR).  IAPs perform a range of functions, one of 
which is to bind to caspases and inhibit their activity (Gyrd-Hansen & Meier, 2010).  
SMAC release into the cytosol from the mitochondria acts to de-repress caspase 
activity by binding and inhibiting IAPs (Du et al, 2000).  cFLIP is closely related to 
caspase 8, but lacks any detectable caspase activity due to catalytic site amino acid 
substitutions, and therefore acts as a dominant negative protein to suppress caspase 
8 activation (Rasper et al, 1998).  CD95 and CD95L are FAS and FAS ligand, 
respectively.  Figure modified and adapted from (Hotchkiss & Nicholson, 2006). 
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p53-REGULATED MICRORNAs: p53-miRs   
 Since elucidation of the first direct p53-target genes nearly 25 years ago, all 
subsequently discovered p53-target genes have been protein-coding genes; however, 
in 2007 the p53 transcriptional network grew to encompass microRNA (miRNA) genes 
when I and others demonstrated that p53 directly regulates transcription of the miR-34a 
locus (He et al, 2007; Paris et al, 2008).  Since this initial finding, p53 has been shown 
to regulate the transcription of a handful of other miRNA loci, and insight into the 
biological functions of the miR-34 family has grown substantially, as I will expand upon 
in Chapter 4.  Below, I will introduce miRNA biogenesis and mechanisms of action in 
mammals, as well as highlight some prominent examples of how miRNAs promote and 
suppress tumorigenesis.  
 
miRNA biogenesis 
 miRNAs are a class of genetically-encoded, small regulatory RNA molecules 
whose mature forms are single-stranded RNAs ranging in length from 21-25 nt.  miRNA 
biogenesis begins by RNA Polymerase II (RNAPII)-dependent transcription of what is 
often a much longer initial RNA species, termed the primary microRNA or pri-miRNA 
(Lee et al, 2004), which is often capped and polyadenylated like protein-coding mRNAs 
(Cai et al, 2004).  pri-miRNAs may also originate from RNA polymerase III-generated 
transcripts (Borchert et al, 2006; Pfeffer et al, 2005). The initial transcript may be the 
product of an independent transcriptional unit (i.e., an intergenic miRNA) that possesses 
its own promoter and termination sequences.  Alternatively, the mature miRNA 
sequence may reside within an intron, or even within the 3’ UTR, of a protein-coding 
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gene (i.e. intragenic) (Rodriguez et al, 2004). After synthesis, pri-miRNAs are 
endonucleolytically cleaved into an ~70 nt-long stem-loop RNA structure by the 
Microprocessor complex which contains the RNAse III enzyme Drosha and its cofactor, 
DGCR8 (also known as Pasha) (Gregory et al, 2004; Han et al, 2006; Lee et al, 2003). 
The pre-miRNA, which contains within it the mature miRNA sequence, is then exported 
to the cytosol via the nuclear export receptor protein Exportin-5 and the GTP-bound 
form of the Ran GTPase (Bohnsack et al, 2004; Kim, 2004; Lund et al, 2004; Yi et al, 
2003). In the cytosol, the pre-miRNA is handed off to another RNAse III enzyme, Dicer, 
which cleaves the pre-miRNA into a shorter, double-stranded RNA with 2 nt 3’ 
overhangs on both strands (Bernstein et al, 2001; Zhang et al, 2002). The last step in 
generating a functional miRNA is the determination of which of the two RNA strands will 
be loaded into the Argonaute (Ago) protein subunit of the multi-protein RNA-induced 
Silencing Complex (RISC), the complex that mediates post-transcriptional gene 
silencing. Strand selection and incorporation into the RISC is largely determined by the 
thermodynamic properties of the double-stranded miRNA (Khvorova et al, 2003; 
Schwarz et al, 2003). The minimal RISC is a heterotrimer containing Dicer, Ago2 and 
TRBP (the human immunodeficiency virus transactivating response RNA-binding 
protein), which can correctly process a supplied pre-miRNA, load the correct strand into 
RISC and efficiently perform target mRNA strand cleavage in vitro (Chendrimada et al, 
2005; Gregory et al, 2005; Maniataki & Mourelatos, 2005).  In vivo, RISC is likely much 
more heterogeneous in composition and contains more proteins than the minimally 
functional trimer (Liu et al, 2005a; Meister et al, 2005; Robb & Rana, 2007).  For 
example, there are four highly related Argonaute proteins in mammals (Ago1-4) 
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Figure 1.7 | miRNA biogenesis and mechanisms of post-transcriptional gene 
silencing (PTGS). miRNAs are transcribed mainly by RNA polymerase II (1), 
although RNA polymerase III-dependent transcription has also been described (see 
main text for reference). Primary miRNA transcripts (pri-miRNAs) may derive from a 
gene encoding just one miRNA (2a), from a polycistronic cluster (2b), or from the 
intronic region of a protein-coding gene (2c).  Following transcription, the pri-miRNA 
is processed by the type III RNase Drosha (3). The newly formed stem–loop 
structure, pre-miRNA, is recognized by the exportin-5:RanGTP complex and is 
transported to the cytoplasm through the NPC (Nuclear Pore Complex).  In the 
cytosol, a second type III RNAse, Dicer, cleaves the loop (4), leaving a double-strand 
fragment, the miRNA:miRNA* duplex (5). The blue strand is the future mature miRNA 
(the guide strand), while the red strand is its antisense miRNA* (the passenger 
strand). The duplex is then unwound and loaded into the miRISC complex (6), where 
it recognizes and anneals to its mRNA target, usually within the 3’ UTR (7). The 
messenger RNA:miRISC complex then mediates translational repression (8a) and/or 
mRNA decay (8b).  Figure adapted from (Araldi & Schipani, 2010). 
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(Sasaki et al, 2003), and RISC can contain any of the four Ago proteins (Yoda et al, 
2010).  Only Ago2 has detectable ‘slicer’ activity in vivo, capable of endonucleolytically 
cleaving a target mRNA when the guide miRNA is perfectly based paired to it (Liu et al, 
2004a; Meister et al, 2004).  Ago 1, 3 and 4 also participate in post-transcriptional gene 
silencing (PTGS), albeit by different mechanisms, as discussed in the next section. 
 
Posttranscriptional regulation of gene expression by miRNAs 
 Once incorporated into RISC, miRNAs can carry out PTGS in one or more ways 
in mammals depending on the specific target mRNA, the specific miRNA loaded into 
RISC and the specific composition of the RISC.  If the mRNA and miRNA perfectly base 
pair to each other in the context of RISC containing Ago2, the mRNA is cleaved to 
generate free 5’ and 3’ RNA ends which trigger rapid mRNA decay (Orban & Izaurralde, 
2005); however, this scenario is rare in mammals.  Rather, most miRNAs imperfectly 
base pair to the target mRNAs through a ‘seed sequence’ of about seven nucleotides 
(nucleotide positions 2-8 from the 5’ end), followed by a random scattering of base pair 
interactions along the rest of the miRNA.  Via this imperfect base pairing, miRNAs 
deliver RISC to their target mRNAs for subsequent PTGS; however, the mechanisms of 
PTGS vary and are to some degree still a topic of debate.  RISC has been shown to 
block translation of target mRNAs, either by inhibiting translation initiation (Chendrimada 
et al, 2007; Pillai et al, 2005), translation elongation (Petersen et al, 2006) or by 
inducing mRNA deadenylation and degradation through canonical pathways (Behm-
Ansmant et al, 2006; Chen et al, 2009; Fabian et al, 2009).  A fourth mechanism, which 
is not necessarily mutually exclusive of those above, is the localization of target mRNAs 
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to P-bodies (Sheth & Parker, 2003), cytosolic RNP granules where translationally-
repressed mRNAs are degraded or stored, possibly for future translation under different 
cellular conditions (Bhattacharyya et al, 2006; Liu et al, 2005b).  Although 
endonucleolytic slicer activity is restricted to Ago2, all four mammalian Ago proteins 
participate in one or more forms of PTGS.  
 
miRNAs as oncogenes and tumor suppressors 
 Not long after the discovery of miRNAs, studies in both human and murine 
systems revealed that aberrant expression of individual miRNAs or miRNA clusters 
could have pathological consequences, including cancer. Coincidently, the first study to 
demonstrate that a mammalian transcription factor could regulate the expression of a 
miRNA gene found that the MYC oncogene positively regulates the expression of the 
miR-17~92 miRNA cluster (O'Donnell et al, 2005).  Concurrently, the miR-17~92 cluster 
was shown to collaborate with MYC to accelerate tumor growth in mouse models (He et 
al, 2005).  Another potentially oncogenic miRNA, miR-21, is overexpressed in some 
cancers and functions in an anti-apoptotic manner (Chan et al, 2005; Ciafre et al, 2005; 
Iorio et al, 2005). Conversely, several studies have revealed that miRNAs can function 
as tumor suppressors as well.  For instance, the expression of miR-15a and miR-16-1 is 
downregulated in some cancers, and these miRNAs are known to directly target the 
anti-apoptotic Bcl-2 protein (Calin et al, 2002; Cimmino et al, 2005).  Similarly, 
downregulation of let-7 miRNA expression has been associated with decreased post-
operative survival in cancer patients (Takamizawa et al, 2004).  Subsequently, let-7 was 
shown to directly repress Ras proto-oncogene expression (Johnson et al, 2005).  
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 My first dissertation project was to identify miRNAs under the transcriptional 
regulation of the p53 tumor suppressor.  While I was ultimately successful (see Chapter 
3), several other groups also identified miR-34a and its family members, miR-34b and 
miR-34c, as direct transcriptional targets of p53 capable of mediating tumor suppressive 
effects (see Discussion, Chapter 4).  As I will also discuss in Chapter 4, several other 
miRNAs have been added to the p53 transcriptional network, and a novel function for 
p53 in miRNA biogenesis has been discovered.  In summary, miRNA expression 
appears hard-wired into many of the canonical oncogenic and tumor suppressive 
signaling pathways, and miRNAs undoubtedly play a role in the pathogenesis of tumor 
formation. 
 
SCIENTIFIC PROBLEM ADDRESSED IN THIS THESIS 
 Prior to beginning my dissertation work, approximately 40,000 scientific papers 
had been published on the topic of p53.  Nearly three decades of study had established 
p53 as a transcription factor and as the most commonly mutated tumor suppressor 
gene in human cancer.  It had been thoroughly demonstrated that p53 can be activated 
by a wide variety of cellular stresses and that p53 activation, in turn, can elicit several 
possible cellular outcomes.  However, one very important question remains 
unanswered: how is cell fate choice determined in response to p53 activation?  In 
other words, how does p53 activation lead to different cellular responses depending on 
i) the nature of the p53-activating signal, and ii) the cell type experiencing the stress? 
 In response to these central questions, a handful of p53-centric models have 
emerged to explain how a given stress signal is converted by the p53 transcriptional 
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network into the appropriate cellular outcome by means of a simple ‘switch’. One simple 
model posits that the absolute level of p53 protein acts as the switch.  This model is 
supported by data obtained by inducible expression of p53 in p53-null cells wherein the 
level of p53 expression is be controlled by a tetracycline-inducible promoter.  The 
authors found that inducing p53 to low levels resulted in a cell cycle arrest phenotype in 
H1299 and Saos-2 cells, whereas higher levels of p53 expression triggered apoptosis 
(Chen et al, 1996). An alternative model postulates that post-translational modification 
of the p53 molecule itself acts as a switch. For example, phosphorylation of Ser46 
(Bulavin et al, 1999; Feng et al, 2006; Yoshida et al, 2006) and acetylation of Lys120 
(Charvet et al, 2011; Sykes et al, 2006; Tang et al, 2006), have been shown to favor the 
apoptotic response by favoring p53 binding and transactivation of pro-apoptotic genes.  
A third model states that p53-binding proteins can modulate the transactivation potential 
of p53 in a gene-specific manner, thus creating an imbalance in the expression of cell 
cycle arrest versus apoptotic genes to favor one specific response over another. For 
example, the HZF zinc finger protein was shown to favor activation of p21, thus leading 
to cell cycle arrest (Das et al, 2007; Sugimoto et al, 2006), whereas the ASPP proteins 
are proposed to facilitate activation of apoptotic genes (Samuels-Lev et al, 2001; Vives 
et al, 2006). However, preliminary data from our lab were inconsistent with these 
models and thus prompted my investigation. In Chapter 2, I present my work on the 
mechanisms of stimulus-specific p53-dependent responses, which led to a new model 
of cell fate choice that integrates p53-dependent and -independent molecular events.  In 
Chapter 3, I show results on mechanisms of cell type-specific cell fate choices, which 
revealed an important role for the first known p53-regulated microRNA, miR-34a.  In 
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Chapter 4, I discuss my key findings in the context of existing dogma and suggest 
additional experiments designed to gain further mechanistic insight and extend my 
findings. 
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CHAPTER II 
A DR4:tBID AXIS DRIVES THE p53 APOPTOTIC RESPONSE BY PROMOTING 
OLIGOMERIZATION OF POISED BAX 
 
ABSTRACT 
 The cellular response to p53 activation varies greatly in a stimulus- and cell type-
specific manner. Dissecting the molecular mechanisms defining these cell fate choices 
will assist the development of effective p53-based cancer therapies and also illuminate 
fundamental processes by which gene networks control cellular behavior. Using an 
experimental system wherein stimulus-specific p53 responses are elicited by non-
genotoxic versus genotoxic agents, we discovered a novel mechanism that determines 
whether cells undergo proliferation arrest or cell death. Strikingly, we observe that key 
mediators of cell cycle arrest (p21, 14-3-3σ) and apoptosis (PUMA, BAX) are equally 
activated regardless of outcome. In fact, arresting cells display strong translocation of 
PUMA and BAX to the mitochondria, yet fail to release cytochrome C or activate 
caspases. Surprisingly, the key differential events in apoptotic cells are p53-dependent 
activation of the DR4 death receptor pathway, caspase 8-mediated cleavage of BID, 
and BID-dependent activation of poised BAX at the mitochondria. These results reveal a 
previously unappreciated role for DR4 and the extrinsic apoptotic pathway in cell fate 
choice following p53 activation.  
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RESULTS 
Cell fate choice to p53 activation is defined by the stimulus-specific activation 
of poised BAX at the mitochondria 
 In order to uncover novel mechanisms contributing to p53-dependent cell fate 
choices, we established a tissue culture system in which p53 activation results in 
different cellular fates depending on the p53-activating agent utilized. Our group and 
others have previously demonstrated that HCT116 cells undergo reversible p53-
dependent cell cycle arrest upon treatment with Nut3 (Paris et al, 2008; Tovar et al, 
2006). In contrast, these same cells undergo robust p53-dependent apoptosis upon 
treatment with 5FU (Figure 2.1A) (Bunz et al, 1999). Interestingly, while both Nut3 and 
5FU induce equivalent p53 protein accumulation, only 5FU causes release of 
cytochrome C into the cytosol, caspase 3 activation and PARP cleavage, demonstrating 
that differences in p53 protein levels do not account for the stimulus-specific responses 
seen in our paradigm (Figure 2.1B).   
 Work from several labs has put forth a model wherein differential transcriptional 
activation of key p53 target genes mediating cell cycle arrest, such as p21 and 14-3-3σ, 
versus genes mediating apoptosis, such as PUMA and BAX, can determine the cellular 
outcome to p53 activation (Das et al, 2007; Samuels-Lev et al, 2001; Sykes et al, 2006; 
Tang et al, 2006). Accordingly, we hypothesized that stimulus-specific regulation of one 
or more of these genes could steer the p53 response toward a specific outcome in our 
system. Interestingly, both Nut3 and 5FU treatment lead to identical accumulation of 
p21 and 14-3-3σ proteins (Figure 2.1B). Thus, although it is well established that these 
two cell cycle regulators are required for p53-dependent cell cycle arrest                     
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Figure 2.1 | Stimulus-specific responses to p53 activation are defined by 
differential BAX oligomerization. (A) HCT116 cells undergo p53-dependent 
apoptosis in response to 5FU, but not Nut3. Cells were treated with Nut3 or 5FU for 
the indicated times, stained with Annexin-V-FITC and analysed by flow cytometry. 
Isogenic p53-null HCT116 cells are denoted as p53-/-. Data shown are the mean ± 
s.d. of at least three independent experiments. (B) Immunoblot analysis reveals that 
several genes mediating cell-cycle arrest and apoptosis are expressed equally in 
response to Nut3 or 5FU treatment. Casp3* denotes the p19/17 doublet indicative of 
caspase 3 activation. (C) Nut3-treated cells accumulate as much mitochondrial 
PUMA and BAX as do 5FU-treated cells. COX4 is a mitochondrial protein serving as 
a loading control. HCT116 cells were treated as in (B) before preparation of 
mitochondrial fractions (see Figure 2.2 for fractionation controls). (D) BAX 
oligomerization is observed only in 5FU-treated cells. Filled circles on the right 
represent the predicted migration of BAX mono-, di-, tri-, and tetramers. (E) Stimulus-
specific activation of the BAX protein was detected by immunoprecipitation with the 
conformer-specific 6A7 antibody followed by western blot.  
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(el-Deiry et al, 1993; Hermeking et al, 1997) and that they cooperate to exert protective 
effects against 5FU-induced apoptosis (Chan et al, 2000), they are clearly not the 
determinants of cell fate choice in our system. PUMA and BAX are direct transcriptional 
targets of p53 required for 5FU-induced apoptosis (Miyashita & Reed, 1995; Nakano & 
Vousden, 2001; Yu et al, 2001). Remarkably, Nut3 treatment induces the accumulation 
of PUMA and BAX proteins to levels equal to or higher than those observed upon 5FU 
treatment (Figure 2.1B). Furthermore, mitochondrial fractionation experiments 
demonstrate that Nut3 treatment leads to effective translocation of PUMA and BAX to 
the mitochondria (Figure 2.1C, fractionation controls are shown in Figure 2.2). These 
observations suggest that physiological induction and mitochondrial accumulation of 
these key apoptotic factors is not sufficient to trigger p53-dependent cell death.  
 The lack of cytochrome C release into the cytosol of Nut3-treated cells suggests 
that MOMP is impaired under these conditions.  One explanation for this could be the 
failure of BAX to oligomerize and form pores in the mitochondrial outer membrane.  To 
test this, we evaluated BAX oligomerization using chemical crosslinking of mitochondrial 
fractions, which revealed the existence of BAX oligomers in 5FU-treated cells but not in 
cells treated with Nut3 (Figure 2.1D).  This suggests that in Nut3-treated cells, BAX fails 
to undergo the requisite conformational change prior to oligomerization (Kim et al, 
2009). We investigated this possibility by immunoprecipitating BAX with the 
conformation-specific antibody 6A7, which specifically detects the activated conformer 
of BAX (Hsu & Youle, 1997).  Confirming our hypothesis, BAX activation is detectable in 
5FU-treated cells, but not in cells treated with Nut3 (Figure 2.1E). Taken together, 
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Figure 2.2 | Immunoblot controls for experiments shown in Figure 2.1C. (A) 
Western blot controls for sub-cellular fractionation/mitochondria isolation 
experiments. HCT116 cells were treated with Nut3 and 5FU for the indicated times 
and separated into cytosolic and mitochondria-enriched fractions. The presence or 
absence of the mitochondrial protein COX4 and the cytosolic protein α-tubulin were 
ascertained by western blot analysis. ’Input (0 h)’ represents total protein from 
untreated HCT116 cells and is shown as a control for enrichment. (B) Total COX4 
and α-tubulin protein levels were also analyzed over the standard time course. 
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these data demonstrate that although Nut3 treatment leads to effective accumulation of 
PUMA and BAX at the mitochondria, it fails to promote BAX oligomerization, MOMP and 
apoptosis. 
BID is required for stimulus-specific BAX activation and apoptosis 
  It is well established that MOMP is regulated by the balance between pro- and 
anti-apoptotic members of the BCL2 protein family, many of which are transcriptionally 
regulated by p53 in some cell types, such as BAX, PUMA, NOXA, BID and BCL2 
(Miyashita et al, 1994b; Miyashita & Reed, 1995; Nakano & Vousden, 2001; Sax et al, 
2002; Schuler et al, 2003; Wu et al, 2001; Yu et al, 2001).  Having ruled out differential 
expression of PUMA and BAX as responsible for stimulus-specific MOMP in our 
system, we next examined the expression of the pro-apoptotic BH3-only proteins 
NOXA, BID, the truncated active form of BID (tBID), as well as the anti-apoptotic 
proteins BCL2 and BCL-XL.  Interestingly, we observed both stimulus-specific induction 
of NOXA protein and proteolytic activation of BID upon 5FU treatment (Figure 2.3A). 
Stimulus-specific activation of NOXA and tBID is also reflected in their mitochondrial 
levels (Figure 2.3B). In contrast, the total and mitochondrial levels of BCL2 and BCL-XL 
remain unchanged by either treatment (Figure 2.3A-B). Differential induction of NOXA is 
also observed at the mRNA level, and in agreement with a previous report (Yu et al, 
2001), we found that NOXA upregulation upon 5FU treatment is p53-independent 
(Figure 2.4). Although BID has been described as a direct transcriptional target of p53 in 
other settings (Sax et al, 2002), BID mRNA expression was not induced by Nut3 or 5FU 
in our system (Figure 2.5). To test if differential activation of NOXA and tBID contributes 
to cell fate choice in our paradigm, we established stable knockdown cell 
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Figure 2.3 | BID cleavage is stimulus-specific and required for BAX 
oligomerization and apoptosis. (A) NOXA and tBID proteins accumulate in 5FU-
treated, but not in Nut3-treated cells, whereas BCL2 and BCL-XL levels are similar 
between treatments. (B) Levels of mitochondria-localized NOXA and tBID increase 
following 5FU, but not Nut3, whereas the levels of BCL2 and BCL-XL remain similar 
between treatments. COX4 panel is same as Figure 1C. (C) Immunoblot assessment 
of NOXA knockdown. (D) Apoptotic index assays show no significant effect of NOXA 
knockdown on 5FU-induced apoptosis. Data shown are the mean ± s.d. (E) Apoptotic 
index assays indicate that BID knockdown abrogates 5FU-induced apoptosis as 
effectively as BAX knockout. Data shown are the mean ± s.d. (F) Western blot 
analysis of BAX dimerization in Nut3 and 5FU-treated cells expressing shCTRL or 
shBID. BID depletion prevents BAX dimerization in response to 5FU treatment. P-
values shown in (D, E) were calculated by Student’s t-test (unpaired, two-tailed).   
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Figure 2.4 | Q-RT-PCR analysis of NOXA mRNA levels. Wild type and p53-/- 
HCT116 cells were treated with Nut3 or 5FU for the indicated times and NOXA 
mRNA expression was quantified by Q-RT-PCR. ‘0 h’ is a vehicle-treated (DMSO) 
control sample representing basal NOXA mRNA expression. Data were normalized 
to 18S rRNA levels and plotted as the fold change relative to the control treatment. 
Data represent the mean ± the s.d. of at least three independent experiments. 
 
 
                          
Figure 2.5 | Q-RT-PCR analysis of BID mRNA levels. Wild type and p53 -/- 
HCT116 cells were treated with Nut3 or 5FU for the indicated times and BID mRNA 
expression was quantified by Q-RT-PCR analysis.  ‘0 h’ is a vehicle-treated (DMSO) 
control sample       representing basal BID mRNA expression.  Data were normalized 
to 18S rRNA levels and   plotted as the fold change relative to control-treated wild 
type cells.  Data represent the mean ± the s.d. of at least three independent 
experiments. 
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lines for each factor and measured the apoptotic response following 5FU treatment.  
Interestingly, reducing NOXA expression well below basal levels has no significant 
effect on 5FU-induced apoptosis (Figure 2.3C-D).  In contrast, BID depletion 
significantly reduces 5FU-induced apoptosis, blocking cell death as effectively as a BAX 
knockout (Figure 2.3E).  Importantly, BID knockdown severely impairs BAX 
oligomerization in 5FU-treated cells (Figure 2.3F).  Taken together, these data 
demonstrate that BID is an important factor mediating apoptosis in response to 5FU, 
and suggests that the failure of Nut3-activated p53 to induce BID cleavage determines 
cell fate choice in our experimental model. 
Stimulus-specific activation of caspase 8 is required for BID cleavage and BAX 
activation 
 Caspase 8 is a major initiator caspase in the death receptor-dependent 
(extrinsic) apoptotic pathway and a known mediator of BID cleavage in response to 
genotoxic stress (Li et al, 1998). Interestingly, we found that only 5FU treatment leads to 
caspase 8 activation (Figure 2.6A) and that this event requires p53 (Figure 2.6B).  
Furthermore, caspase 8 knockdown strongly inhibits activation of executioner caspase 
3, and cleavage of the caspase 3 substrate PARP (Figure 2.6C). In fact, caspase 8-
deficient cells are significantly impaired in their ability to undergo apoptosis following 
5FU treatment (Figure 2.6D).  Next, we asked whether caspase 8 is required for BID 
cleavage in our system and found that indeed, proteolytic processing of BID is greatly            
reduced in 5FU-treated cells lacking caspase 8 (Figure 2.6E). Expectedly, BID cleavage 
upon 5FU treatment also requires p53 (Figure 2.6B). Importantly, BAX activation is 
significantly blocked in cells depleted of caspase 8 or BID as seen by 
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Figure 2.6 | Caspase 8 activation is stimulus-specific, p53-dependent and 
required for BID cleavage and BAX activation. (A) Caspase 8 activation is 
stimulus-specific. (FL) indicates full-length caspase 8 (55–57 kDa), Casp8* indicates 
the 43–41 kDa cleavage products. (B) 5FU-induced caspase 8 activation and BID 
cleavage in HCT116 cells are p53-dependent events. (C) Caspase 8 knockdown 
prevents caspase 3 activation and PARP cleavage upon 5FU treatment. White line 
indicates cropping of intervening lanes from the same blot. (D) Apoptotic index 
assays show that caspase 8 is required for 5FU-induced apoptosis. Data shown are 
the mean ± s.d. P-values were calculated by Student’s t-test (unpaired, two-tailed). 
(E) BID cleavage in 5FU-treated cells requires caspase 8. (F) Immunoblot analysis of 
6A7 immunoprecipitates indicates that BAX activation following 5FU treatment is both 
caspase 8- and BID-dependent.  
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immunoprecipitation with 6A7 antibody (Figure 2.6F). Stimulus-specific activation of 
caspase 8 was also observed in RKO colorectal cancer cells, which also undergo cell 
cycle arrest upon Nut3 treatment (Figure 2.7) (Tovar et al, 2006). As observed for 
HCT116 cells, caspase 8 knockdown impairs BID cleavage, caspase 3 activation, 
PARP cleavage and apoptosis in this cell line (Figure 2.7). In sum, these data indicate 
that stimulus-specific activation of the extrinsic apoptotic pathway involving p53, 
caspase 8 and tBID is required for BAX activation and commitment to apoptosis in our 
paradigm. 
Differential activation of the extrinsic pathway requires FADD, not TRADD     
 In an effort to understand in greater detail how Nut3 and 5FU differ in their ability 
to trigger p53-dependent apoptosis, we investigated the signaling pathway responsible 
for caspase 8 activation upon 5FU treatment.  Of note, caspase 8 can be directly 
activated downstream of death receptors, but also by a death receptor-independent 
mechanism involving caspase 3 (von Haefen et al, 2003).  To discriminate between 
these possibilities, we established stable knockdown cell lines for FADD and TRADD 
(shFADD and shTRADD), two important death domain-containing adaptor proteins that 
transmit death ligand signals from death receptors to caspase 8 (Jin & El-Deiry, 2005).  
If 5FU-induced caspase 8 activation requires either of these adaptor proteins, this would 
suggest that caspase 8 is activated via death receptors in our experimental setting. 
Indeed, we found that FADD depletion abrogates both caspase 3 activation and 
Annexin-V positivity, whereas depletion of TRADD does not significantly affect either 
event (Figure 2.8A-B).  Furthermore, shFADD cells are impaired in their ability to 
activate BAX (Figure 2.8C). Together, these results indicate that 5FU treatment causes 
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Figure 2.7 | Caspase 8-dependent apoptosis in response to 5FU is also 
observed in RKO colorectal cancer cells. (A) Western blot analysis indicates that 
caspase 3 activation is impaired in caspase 8-deficient (shCasp8) RKO colorectal 
carcinoma cells following 48 h of 5FU treatment. tBID accumulation and PARP 
cleavage are also severely attenuated in shCasp8 RKO cells. (FL) denotes the full-
length zymogen forms of caspase 8.  Casp8* and Casp3* indicate the cleaved 
(activated) forms of the caspases. Nucleolin served as a loading control.  (B) 
Apoptotic index assays demonstrate that caspase 8 is required for full induction of 
apoptosis in RKO cells upon 5FU treatment.  Data shown are the mean ± the s.d.     
P values were calculated by Student's t-test (unpaired, two-tailed). 
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apoptosis through a FADD-dependent, TRADD-independent pathway.  Additionally, we 
observed that BID knockdown impairs caspase 3 activation more than it does caspase 8 
activation, providing additional evidence that caspase 8 activation occurs upstream of 
caspase 3 activation in 5FU-treated HCT116 cells (Figure 2.9).  Thus, we conclude that 
the key molecular event defining cell fate choice in our model system likely resides in 
the death receptor pathway. 
DR4 is required for BAX activation and apoptosis 
 We hypothesized that one or more death receptors acting upstream of FADD 
may be differentially expressed upon p53 activation by Nut3 versus 5FU. To test this, 
we examined the expression and cell surface localization of DR4 
(TNFRSF10A/APO2/TRAIL-R1), DR5 (TNFRSF10B/TRAIL-R2/KILLER) and FAS 
(TNFRSF6/APO-1/CD95), all of which require FADD to mediate pro-apoptotic signaling 
and have also been previously described as p53 target genes (Jin & El-Deiry, 2005; Liu 
et al, 2004b; Muller et al, 1998; Wu et al, 1997). Western blot analysis of the three death 
receptors revealed markedly different, stimulus-specific patterns of expression for DR4, 
DR5 and FAS (Figure 2.10A). At an early time point (8 h), Nut3 induces DR4 to the 
same extent as 5FU; however, in Nut3-treated cells DR4 protein returns to basal levels 
at later time points (16 and 24 h) but remains elevated in 5FU-treated cells.  In contrast, 
DR5 expression is induced equally by Nut3 and 5FU at 8 h, but Nut3-treated cells 
maintain steady DR5 expression, whereas DR5 protein levels decrease slightly in 5FU-
treated cells at later time points. Lastly, both Nut3 and 5FU treatments lead to sustained 
FAS induction over the course of the experiment, although 5FU does induce FAS to a 
greater extent than Nut3. Next, we investigated the cell surface expression of 
  51  
 
 
Figure 2.8 | Stimulus-specific activation of the extrinsic apoptotic pathway is 
mediated by FADD. (A) Caspase 3 activation requires the adaptor protein FADD, 
not TRADD. (B) Apoptotic index assays demonstrate that FADD, not TRADD, is 
required for full induction of apoptosis upon 5FU treatment. Data shown are the 
mean ± s.d. P-values were calculated by Student’s t-test (unpaired, two-tailed). (C) 
Immunoblot analysis of 6A7 immunoprecipitates indicates that BAX activation 
following 5FU treatment is FADD-dependent.  
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Figure 2.9 | BID knockdown blocks caspase 3 activation more significantly than 
caspase 8 activation. HCT116 cell lines expressing control or BID shRNAs were 
treated with Nut3 or 5FU for 24 h and subjected to either mitochondrial fractionation 
or processed for total protein followed by western blot analysis of caspase 8 and 
caspase 3 activation. HCT116 cells stably expressing a non-targeting control shRNA 
were treated with DMSO, Nut3 or 5FU (three leftmost lanes) and serve as controls for 
BID knockdown and drug treatment. ‘mitochondria’ denotes western blots performed 
on mitochondria-enriched fractions.  α-tubulin and COX4 are loading controls for the 
total and mitochondria-enriched fractions, respectively. Casp8* and Casp3* indicate 
the cleaved (activated) forms of the caspases. 
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DR4, DR5 and FAS by flow cytometry, which is a more accurate measurement of the 
active pool of these receptors.  In close agreement with total protein levels, 5FU 
treatment leads to higher cell surface levels of DR4 than does Nut3 treatment, with 
Mean Fluorescence Indices (MFIs) of 1.34 ± 0.04 and 1.04 ± 0.03, respectively (Figure 
2.10B). In contrast, despite differences in the total protein levels seen by Western blot, 
cell surface levels of FAS and DR5 are nearly identical in cells treated with Nut3 or 5FU 
(MFIFAS 2.10 ± 0.04 and 2.07 ± 0.05; MFIDR5 1.47  ± 0.08 and 1.40 ± 0.12).  Based on 
these results, we focused our efforts on testing the possible role of DR4 in 5FU-induced 
apoptosis. Interestingly, whereas FAS knockdown has no significant effect on cell 
death, knocking down DR4 expression significantly attenuates 5FU-induced apoptosis 
(Figure 2.10C). Next, we tested if DR4 is required for 5FU-induced BAX activation.  
Indeed, immunoprecipitation of activated BAX with the 6A7 antibody revealed that DR4 
ablation blocks BAX activation upon 5FU treatment (Figure 2.10D). Importantly, DR5 
has been previously shown to contribute to 5FU-induced apoptosis (Wang & El-Deiry, 
2004), and we confirmed these results in our system (Figure 2.11). Thus, although both 
DR4 and DR5 mediate the apoptotic effects of this genotoxic agent, only DR4 is 
differentially activated in 5FU treated cells as compared to Nut3-treated cells, and thus 
is more likely to define the cell fate choice. 
Stimulus-specific DR4 expression is achieved via stabilization of the DR4 
mRNA 
 Next, we investigated the mechanism driving stimulus-specific activation of DR4. 
Interestingly, Q-RT-PCR analysis reveals stimulus-specific induction of the DR4 mRNA 
over time (Figure 2.12A). Importantly, full induction of DR4 mRNA requires p53, 
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Figure 2.10 | DR4 is required for stimulus-specific BAX activation and 
apoptosis. (A) Immunoblots show that total protein levels of the DR4 and FAS death 
receptors, but not DR5, are higher in 5FU-treated cells than in those treated with 
Nut3. (*) Indicates a non-specific band. (B) Nut3 fails to induce DR4 cell surface 
expression as measured by flow cytometry. Nut3 and 5FU induce DR5 and FAS cell 
surface localization equally. Data shown are representative of at least three 
independent experiments. (C) Apoptotic index assays show that DR4, but not FAS, is 
required for 5FU-induced apoptosis (see Figure 2.11A for western blot analysis of 
FAS knockdown). Data shown are the mean ± s.d. P-values were calculated by 
Student’s t-test (unpaired, two-tailed). (D) Immunoblot analysis of 6A7 
immunoprecipitates indicates that BAX activation following 5FU treatment is DR4-
dependent. 
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however, the mRNA still accumulates ~2 fold in p53-null cells, suggesting the combined 
action of p53-dependent and p53-independent events. In contrast, the p21 mRNA was 
equally induced by both drugs in a p53-dependent manner. Since the DR4 locus is a 
known direct transcriptional target of p53 (Liu et al, 2004b), we hypothesized that 
stimulus-specific transcription of DR4 could explain differential DR4 expression.  To test 
this, we measured initiating and elongating forms of RNA polymerase II (Ser5-phospho-
RNAPII and Ser2-phospho-RNAPII, respectively) at the DR4 locus by Chromatin 
Immunoprecipitation (ChIP) assays. Activation of p53 with Nut3 or 5FU for 12 h results 
in increased S5P-RNAPII occupancy at the DR4 promoter region as well as within the 
gene body, indicating increased transcription initiation with both stimuli (Figure 2.12B). 
Likewise, S2P-RNAPII also increases throughout the DR4 gene body after both 
treatments, surprisingly demonstrating equivalent increases in transcriptional 
elongation. We employed the p21 locus for comparison purposes, which displays strong 
RNAPII activation by both p53-activating agents.  Taken together, these results suggest 
that the stimulus-specific accumulation of DR4 mRNA seen in our system cannot be 
adequately explained by stimulus-specific differences in DR4 transcription. Therefore, 
we asked whether Nut3 and 5FU differentially affect DR4 mRNA stability. Indeed, 
mRNA half-life assays demonstrate that 5FU treatment has a significant effect on DR4 
mRNA stability, nearly doubling its half-life relative to DMSO- or Nut3-treated cells 
(Figure 2.12C and Table 2.1).  Interestingly, the DR4 mRNA was also stabilized in p53 -
/- cells. Taken together, these data suggest that Nut3 and 5FU treatments lead to an 
equal but modest induction of DR4 transcription, but that stimulus-specific accumulation 
of DR4 following 5FU treatment results from increased stabilization of the DR4 mRNA. 
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Figure 2.11 | DR5 is required for 5FU-induced apoptosis.  (A) Western blot 
analysis of FAS expression in HCT116 shFAS cells analyzed in Figure 2.10.  
Nucleolin served as a loading control. (B) HCT116 cells require DR5 expression for 
full induction of apoptosis in response to 5FU treatment. Western blot analysis of 
DR5 expression in control (shCTRL) and DR5-deficient (shDR5) HCT116 cells 
treated with   vehicle (DMSO) or 5FU for 24 h. A non-specific, cross-reacting band 
detected by the anti-DR5 antibody is denoted by an asterisk (*).  (C) Western blot 
analysis demonstrates that activation of both caspase 8 and caspase 3 is 
significantly reduced in DR5-deficient (shDR5) HCT116 cells as compared to control 
cells. (FL) denotes the full-length zymogen forms of caspase 8. Casp8* and Casp3* 
indicate the cleaved (activated) forms of the caspases. Nucleolin served as a    
loading control.  (D) Apoptotic index assays demonstrate that DR5 is required for full 
induction of apoptosis in HCT116 cells upon 5FU treatment.  Data shown are the 
mean ± the s.d. P values were calculated by Student’s t-test (unpaired, two-tailed). 
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Of note, the NOXA mRNA, which is also induced in a p53-independent manner upon 
5FU treatment (Figure 2.4), is also strongly stabilized by 5FU regardless of p53 status. 
However, mRNA stabilization upon 5FU is not a universal phenomenon, as it was not 
observed for the p53 target gene MDM2 (Figure 2.12C and Table 2.1). Thus, we 
conclude that 5FU induces mRNA stabilization of a subset of genes in a p53-
independent manner, and in the case of DR4, this event contributes to cell fate choice 
upon p53 activation. 
Conserved action of the DR4/FADD/caspase 8/tBID axis 
 In order to test whether the mechanism of cell fate choice identified in HCT116 
colorectal cancer cells is conserved in cancer cells of different tissue origin, we 
employed H460 cells (non-small cell lung cancer), which also undergo cell cycle arrest 
upon Nut3 treatment (Tovar et al, 2006). Indeed, we found that although both Nut3 and 
5FU activate p53 in this cell line, only 5FU triggers caspase 8 activation, BID cleavage 
and caspase 3 activation  (Figure 2.13A). As observed in HCT116 cells, differential 
induction of apoptosis correlated with higher expression of DR4 protein and mRNA at 
late time points of 5FU treatment (Figure 2.13A-B). Importantly, knockdown of BID, 
caspase 8, DR4 and FADD decreases BID cleavage, activation of caspase 3 and 
Annexin-V staining in this cell line (Figure 2.13C-D). Thus, we conclude that the 
DR4/FADD/caspase 8/tBID axis contributes to cell fate choice across cancer cells of 
different origins.  
 Finally, we investigated whether this same pathway is activated by other 
genotoxic stimuli. To test this, we performed a side-by-side comparison of the effects of 
Nutlin-3, 5FU, doxorubicin, camptothecin, etoposide and Ultra Violet Light C (UVC) on 
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Figure 2.12 | Stimulus-specific stabilization of the DR4 mRNA. (A) Q-RT–PCR 
analysis reveals that the DR4 mRNA, but not the p21 mRNA, accumulates more 
strongly in 5FU-treated cells. (B) ChIP analysis of the DR4 and p21 loci show 
increased levels of initiating (S5P-RNAPII) and elongating (S2P-RNAPII) forms of 
RNAPII in response to p53 activation by both Nut3 and 5FU. Grey regions represent 
the transcribed region of each locus, arrows indicate transcription start sites, black 
boxes represent exons, and black dashes indicate the position of PCR amplicons 
used for analysis of ChIP-enriched DNA. (C) Schematic of experimental procedure 
for DR4 mRNA half-life determination (top). Following 12 h of DMSO, Nut3, or 5FU 
treatment of HCT116 cells of different p53 status, RNA synthesis was halted by ActD 
and the levels of DR4, NOXA, and MDM2 mRNA levels were measured at the 
specified times, revealing that 5FU treatment leads to stabilization of the DR4 and 
NOXA mRNAs in a p53- independent fashion. The numbers to the right indicate the 
mRNA half-lives for the corresponding mRNAs in HCT116 p53 -/- cells treated with 
DMSO (black) or 5FU (blue). All half-life measurements can be found in Table 2.1. 
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Table 2.1 | Table of mRNA half-lives for data shown in Figure 2.12C. DR4, NOXA 
and MDM2 mRNA half-lives were determined in wild type (p53+/+) and p53-null (p53-
/-) HCT116 cells treated with vehicle only (DMSO), Nut3 or 5FU for 12 h prior to 
treatment with Actinomycin D (see Figure 2.12C for experimental scheme). Half-lives 
are shown in hours. 
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Figure 2.13 | The DR4/FADD/caspase 8/tBID axis also defines cell fate choice in 
the H460 lung cancer cell line. (A) Western blot analysis of H460 cells shows that 
both Nut3 and 5FU activate p53 effectively, yet only 5FU leads to caspase 8 
activation, tBID formation and caspase 3 activation. Differential cell fate choice 
correlates with higher levels of DR4 at late time points after 5FU treatment. (B) Q-
RT–PCR analysis shows that the DR4 mRNA accumulates only in 5FU-treated H460 
cells. (C) Knockdown of BID, caspase 8, DR4, and FADD impaired both tBID 
formation and activation of the executioner caspase 3. Immunoblot assessment of 
knockdown efficiency in H460 cells is shown in Figure 2.14. (D) Apoptotic index 
assays reveal that BID, caspase 8, DR4, and FADD are all required for efficient 
induction of apoptosis upon 5FU treatment. Data shown are the mean ± s.d. The 
indicated P-values represent the statistical significance of the 5FU-treated value for 
the respective knockdown line relative to the CTRL shRNA value and were 
calculated by Student’s t-test (unpaired, two-tailed). 
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caspase activation and apoptosis. Although all of these drugs lead to p53 activation, we 
and others have previously shown that only 5FU and UVC lead to rapid apoptosis in 
HCT116 cells, whereas the topoisomerase inhibitors lead to cell cycle arrest mostly in 
G2/M, and to a lesser extent, in G1 (Bunz et al, 1998; Bunz et al, 1999; Donner et al, 
2007a; Gomes & Espinosa, 2010). Interestingly, only 5FU and UVC lead to activation of 
caspase 8 (Figure 2.15). In order to define if 5FU and UVC induced apoptosis by 
identical mechanisms, we tested the impact of shRNAs against BID, caspase 8, DR4 
and FADD as well as p53 knock-out on UVC-induced apoptosis. Expectedly, p53 knock-
out significantly reduced caspase 3 activation upon UVC. Importantly, we found that 
whereas knockdown of BID, caspase 8 and FADD impaired activation of caspase 3 
after UVC, the effects of DR4 knockdown were negligible. Thus, we conclude that both 
5FU and UVC require a functional FADD/caspase 8/BID axis to induce apoptosis, but 
that only 5FU requires DR4, suggesting that UVC utilizes an alternative pathway for 
caspase 8 activation. 
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Figure 2.14 | Western blot validation of H460 knockdown cell lines.  The 
efficiency of target gene knockdown by the indicated shRNAs was determined by 
western blot analysis of the same protein lysates shown in Figure 2.13. ‘CTRL’ 
represents the non-targeting control shRNA used throughout the study.  (FL) 
indicates the full-length precursor forms of caspase 8. 
 
 
 
 
 
 
 
Figure 2.15 | UVC-induced activation of caspase 8 and caspase 3 in HCT116 
cells also requires components of the extrinsic apoptotic pathway. (A) Western 
blot analysis of p53 activation and caspase 8 activation (Casp8*) in wild-type 
HCT116 cells treated with the indicated p53-activating agents for 24 h.  Nucleolin 
served as a loading control. ‘UVC’ indicates treatment with ultraviolet C radiation (see 
Materials and Methods section for details).  (B) Western blot analysis of UVC-
induced caspase 3 activation (Casp3*) in the indicated HCT116 cell lines 24 h after 
UVC irradiation.  α-tubulin served as a loading control.  ‘+/+’ and ‘-/-’ refer to HCT116 
cell lines that are wild type or null for both p53 alleles, respectively. 
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CHAPTER III 
THE miR-34a MICRORNA MODULATES THE CELLULAR RESPONSE TO THE 
SMALL-MOLECULE MDM2 INHIBITOR, NUTLIN-3a 
 
  
ABSTRACT 
 The cellular response to Nutlin-3, a small-molecule inhibitor of the p53 repressor 
MDM2, varies widely among human cancer-derived cell types. Whereas HCT116 
colorectal carcinoma cells display sustained cell cycle arrest, BV173 leukemia cells 
undergo rapid apoptosis and other cell lines show an intermediate response. We found 
that the expression of the p53 target genes p21, 14-3-3σ and the microRNA miR-34a 
correlates tightly with the cell fate choice adopted. All three genes were strongly 
induced in arresting cells, but silenced in cells undergoing Nutlin-3-induced apoptosis. 
In contrast, key apoptotic p53 target genes were equally expressed in arresting and 
apoptotic cells. Interestingly, we establish that miR-34a cooperates with p21 and 14-3-
3σ to override the apoptotic signals generated by p53 activation. Strikingly, p53 binding 
to chromatin and p53-mediated recruitment of certain coactivators to all three target loci 
does not vary among cell types. Instead, the cell type-specific silencing of these genes 
is due to enhanced p21 mRNA degradation, 14-3-3σ promoter DNA methylation and 
reduced processing of the miR-34a primary transcript. Thus, p53-independent events 
regulating expression of protein-coding genes and microRNAs within the network can 
define the cellular outcome of p53 activation. 
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RESULTS 
Distinct responses to p53 activation by Nutlin-3 correlate with differential 
expression of p21 and 14-3-3σ  
 In order to study mechanisms of cell type-specific responses to p53 activation, 
Dr. Ramiro Paris in our lab analyzed the cellular response to Nutlin-3 treatment in a 
panel of cell lines expressing wild type p53. Using FACS analysis of DNA content and 
phosphatidyl-serine exposure, varied responses after identical treatment were observed 
(Figure 3.1). At one end of the spectrum, HCT116 colorectal carcinoma cells show 
negligible signs of apoptosis even at 48 h post-treatment. DNA content profiles indicate 
that HCT116 cells undergo cell cycle arrest in G1 and G2/M with depletion of cells in S 
phase. In sharp contrast, chronic myelogenous leukemia (CML) BV173 cells undergo 
rapid apoptosis, as seen by increased sub-G1 population and Annexin-V staining. A549 
lung cancer cells respond similarly to HCT116 cells, whereas SJSA osteosarcoma cells 
and LNCaP prostate cancer cells show an intermediate response. Expectedly, Nutlin-3 
produced no effects on HCT116 p53 -/- and K562 cells (CML, p53 null) (data not 
shown).  Ramiro hypothesized that differential expression of p53 target genes may drive 
the response adopted by different cell types. To test this, he analyzed expression of 
diverse p53 target genes at the mRNA and protein levels, beginning with Q-RT-PCR 
analysis of HCT116 and BV173 cells, which revealed important differences between the 
two cell types (Figure 3.2A). Interestingly, BV173 cells display significantly lower levels 
of p21 and 14-3-3σ mRNAs both before and after Nutlin-3 treatment. These differences 
are clearly gene-specific, as the mRNAs for PUMA and PIG3 reach similar levels upon 
induction in both cell types. Several other p53 target genes, including MDM2, BTG2, 
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Figure 3.1 | Cell type-specific responses to Nutlin-3. Cultures were treated with 
Nutlin-3 for the indicated time points before analysis of DNA content (A and C) and 
apoptotic index (B and D). Average levels of DNA degradation and phosphatidyl-
serine exposure from three independent experiments are displayed for all five cell-
lines (A and B). Raw data from one representative experiment is shown for HCT116 
and BV173 cells (C and D, 48 h treatment). 
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GADD45a and FAS/APO1 also showed equivalent expression (Figure 3.3). Importantly, 
Western Blots revealed that Nutlin-3 treatment leads to equivalent p53 stabilization and 
PUMA induction in both cell types, yet accumulation of p21 and 14-3-3σ proteins is only 
observed in HCT116 cells (Figure 3.2B). Of note, concurrent activation of p21, 14-3-3σ 
and PUMA in HCT116 cells results in cell cycle arrest, suggesting that the apoptotic 
program is overridden in this scenario and that the dosage of cell cycle inhibitors may 
define the cellular response to Nutlin-3. This notion is further supported by analysis of 
other cell lines (Figure 3.2C). A549 cells, which respond similarly to HCT116 cells, 
express both p21 and 14-3-3σ. SJSA and LNCaP cells, which show an intermediate 
response, express p21 but not 14-3-3σ. Furthermore, a detailed kinetic analysis 
indicates that the delayed onset of apoptosis in SJSA cells correlates with decreased 
p21 expression over time (Figure 3.4). In summary, these data establish a strong 
correlation between expression of p21 and 14-3-3σ and the cellular response adopted.  
Lack of p21 and 14-3-3σ  sensitizes colorectal carcinoma cells to Nutlin-3-
induced apoptosis 
 The anti-apoptotic effects of p21 and 14-3-3σ have been previously established 
when analyzing the cellular response to genotoxic p53-activating agents (Chan et al, 
2000). To define the role of these two cell cycle inhibitors in cell fate choice upon non-
genotoxic activation of p53, Ramiro employed HCT116 cells where both genes have 
been knocked-out (Chan et al, 2000). After prolonged Nutlin-3 treatment, parental 
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Figure 3.2 | p21, 14-3-3σ and miR-34a protect cells from the apoptotic effects of 
Nutlin-3. (A) Q-RT-PCR analysis reveals differential expression of p21 and 14-3-3σ 
in HCT116 versus BV173 cells. Cultures were treated with Nutlin-3 for the indicated 
times before RNA extraction and RT-PCR. 18s rRNA was used for normalization. (B) 
Western Blot analysis showing cell type-specific accumulation of p21 and 14-3-3σ 
proteins after Nutlin-3 treatment. (C) Western Blot showing induction of p21 and/or 
14-3-3σ expression in Nutlin-3-treated (24 h) A549, SJSA and LNCaP cells. (D) 
Comparative analysis of parental versus double knock-out HCT116 cells 
demonstrates the anti-apoptotic effects of p21 and 14-3-3σ during Nutlin-3 treatment. 
(E) Strong correlation between overall miR-34a expression and the cellular response 
to Nutlin-3 among cancer cell types. Cells were treated with Nutlin-3 for 16 h before 
extraction of small RNAs and Taqman assays. U6 snRNA was used as normalization 
control. (F) Knock-down of miR-34a increases the apoptotic effects of Nutlin-3 in p21-
/- 14-3-3-/- HCT116 cells. Control or anti-miR34a LNA-oligonucleotides were 
transfected 24 h prior to Nutlin-3 addition. Apoptotic indexes were performed at 96 h 
post-treatment. Error bars indicate standard deviations over three independent 
experiments. 
 
 
A549
- +
LnCAP
- +Nutlin-3:
SJSA
- +
p21
14-3-3!
Actin
C
p21
re
la
ti
v
e
e
x
p
re
s
s
io
n
10
12
6
4
8
2
0 168 0 168time (h):
14-3-3!
re
la
ti
v
e
e
x
p
re
s
s
io
n
4
5
2
3
1
0 168 0 168time (h):
PUMA
re
la
ti
v
e
e
x
p
re
s
s
io
n
4
5
2
3
1
0 168 0 168time (h):
PIG3
re
la
ti
v
e
e
x
p
re
s
s
io
n
20
25
10
15
5
0 168 0 168time (h):
Q-RT-PCR
HCT116 BV173
A
14-3-3!
PUMA
p21
p53
0 4 8 12 16
Actin
0 4 8 12 16time (h):
HCT116 BV173
B
S
p
h
a
s
e
c
e
ll
s
(%
)
25
30
15
10
20
5
0 9672 0 9672time (h):
A
n
n
e
x
in
V
p
o
s
it
iv
e
c
e
ll
s
(%
)
30
36
18
12
24
6
0 9672 0 9672time (h):
HCT116 HCT116 p21-/- 14-3-3! -/-
D
E
HCT116 SJSA LNCaP BV173
- + - + - + - +
2
4
6
8
10
re
la
ti
v
e
e
x
p
re
s
s
io
n
miR-34a
Nutlin-3:
F
Annexin V
P
I
None + Nutlin-3
12%
13%
27%
43%
None + Nutlin-3
Annexin V
P
I
Annexin V
P
I
Annexin V
10
4
10
3
10
2
10
1
10
4
10
3
10
2
10
1
10
4
10
3
10
2
10
1
10
4
10
3
10
2
10
1
10
4
10
3
10
2
10
1
10
4
10
3
10
2
10
1
10
4
10
3
10
2
10
1
10
4
10
3
10
2
10
1
P
I
Control anti-miR
anti-miR-34a
  68  
HCT116 cells remain arrested and show low levels of cell death (Figure 3.2D). In 
contrast, p21-/- 14-3-3σ -/- cells show reduced arrest and increased apoptosis, confirming 
the notion that p21 and 14-3-3σ play a protective role against Nutlin-3-induced 
apoptosis. However, the level of apoptosis in the double knockout cells did not reach 
that observed for BV173 cells, which lead us to hypothesize the existence of additional 
anti-apoptotic factors. 
miR-34a cooperates with p21 and 14-3-3σ  to influence cell fate choice in 
response to Nutlin-3 treatment 
 In 2007, I and several other labs found that miR-34a is a p53-inducible miRNA, 
and many groups had demonstrated that the miR34a locus is indeed a direct 
transcriptional target of p53 (see Chapter 1).  Concurrent with Ramiro’s work on p21 
and 14-3-3σ expression across multiple cell types, I was measuring miR-34a levels in 
the same cell types using TaqMan Q-RT-PCR assays in some exploratory experiments 
aimed at correlating miR-34a expression with the cellular response to Nutlin-3 (Figure 
3.2E).  While miR-34a is induced by Nutlin-3 in all p53-expressing cell lines, important 
differences in overall miR-34a levels are evident, with HCT116 cells showing the 
highest expression and BV173 cells the lowest. Clearly, miR-34a levels correlate 
negatively with the apoptotic efficacy of Nutlin-3, which led me to hypothesize that miR-
34a may play an anti-apoptotic role in cells treated with Nutlin-3. To test this, I utilized 
Locked-Nucleic Acid (LNA) technology to decrease endogenous miR-34a activity in 
HCT116 p21-/- 14-3-3σ -/- cells. Transfection of anti-miR-34a, but not of control 
oligonucleotides, enhanced Nutlin-3-induced apoptosis as seen by an increase in the 
percentage of Annexin-V-positive cells (27% to 43%, Figure 3.2F). Overall, we conclude 
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that p21, 14-3-3σ and miR-34a collaborate to suppress the p53-dependent apoptotic 
program in Nutlin-3-treated cells.  
p53-dependent induction of p21 is suppressed at post-transcriptional steps in 
BV173 cells 
 Having defined a role for p21, 14-3-3σ and miR-34a in cell fate choice upon 
Nutlin-3 treatment, Ramiro and I investigated the mechanisms driving cell type-specific 
expression of these genes. Influenced by our past work on stimulus-specific 
transcriptional regulation of p53 target genes (Donner et al, 2007a; Donner et al, 2007b; 
Espinosa et al, 2003), Ramiro hypothesized that differential accumulation of p21 mRNA 
in HCT116 versus BV173 cells could be due to transcriptional events. To test this, he 
performed ChIP analysis of the p21 locus and found that induced levels of chromatin-
bound p53 were equivalent in both cell types  (Figure 3.5A).  Transcriptional activation 
by p53 involves recruitment of histone acetyl-transferases (HATs) to the promoter 
region of target genes (Espinosa & Emerson, 2001). Importantly, ChIP assays detected 
high levels of acetylated histone H4 (Ac-H4) upstream of the p21 promoter in both cell 
types, suggesting that p53-mediated recruitment of HATs is not impaired in BV173 cells 
(Figure 3.5A). Transcriptional activation of p21 occurs at post-initiation steps and 
involves conversion of paused RNAP II into the elongating form of the enzyme 
(Espinosa et al, 2003).  Accordingly, significant amounts of pre-loaded RNAP II were 
detected at the p21 proximal promoter in both HCT116 and BV173 cells. Upon Nutlin-3 
treatment, a significant increase in RNAP II occupancy was observed within the 
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Figure 3.3 | Q-RT-PCR analysis of additional p53-target genes in HCT116 and 
BV173 cells.  The expression of four additional p53-target genes involved in 
regulation of p53 expression/function (MDM2), cell cycle arrest (BTG2, GADD45a) or 
apoptosis (FAS/APO1) was measured in HCT116 and BV173 cells treated with 
Nutlin-3 for the indicated times.  Error bars represent the s.d. of at least three 
independent experiments.  
 
 
Figure 3.4 | Delayed onset of apoptosis in SJSA cells correlates with decreased 
p21 expression and lack of 14-3-3σ  expression. Cultures were treated with Nutlin-
3 for the indicated times before concurrent analysis of apoptotic index, DNA content 
profile and protein expression.  (A) Apoptotic index assays showing delayed 
apoptotic response in Nutlin-3-treated SJSA cells. (B) Western Blots showing 
transient induction of p21 protein and lack of 14-3-3σ expression in SJSA cells as 
compared to HCT116 cells.  
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intragenic region in both cell types (amplicons +507, +4001 and +8566), indicative of 
RNAP II activation. RNAP II elongation is more easily visualized when using antibodies 
against phosphorylated Serine 2 within the C-terminal domain repeats of its largest 
subunit (S2P-CTD), a modification that accumulates toward the 3’ end of genes.  ChIP 
analysis showed that S2P-CTD signal is effectively induced in both HCT116 and BV173 
cells, suggesting that the p21 gene is transcriptionally activated to similar extent in both 
cell types (Figure 3.5A). 
 To confirm that the p21 locus is transcriptionally active in BV173 cells, Ramiro 
performed nuclear run-on assays. These experiments detected de novo synthesis of 
p21 mRNA in both HCT116 and BV173 cells, with the transcription rate increasing 
about 3-fold upon Nutlin-3 treatment (Figure 3.5B). Based on these results, he 
hypothesized that differences in steady-state p21 mRNA levels could be due to effects 
on mRNA turnover. To test this, Ramiro performed mRNA half-life assays, which 
demonstrated that p21 mRNA half-life is significantly shorter in BV173 cells (~43 
minutes) than in HCT116 cells (~195 minutes) (Figure 3.5C). In contrast, the PUMA 
mRNA half-life is nearly identical in both cell types, suggesting the action of gene-
specific mRNA stabilization/destabilization mechanisms. Importantly, the mRNA half-
lives for p21 and PUMA are similar before and after Nutlin-3 treatment, indicating that 
the differences in mRNA stability are not dependent on p53 activity. In summary, these 
results indicate that repression of p21 expression in BV173 cells occurs at post-
transcriptional steps, in a p53-independent process likely involving enhanced mRNA 
degradation in BV173 cells; however, additional post-transcriptional mechanisms  
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Figure 3.5 | p21 induction is suppressed at post-transcriptional steps in BV173 
cells. (A) ChIP analysis of the p21 locus indicates that p53 binding, histone 
acetylation and RNAP II activation is equivalent in HCT116 and BV173 cells. Cells 
were treated with Nutlin-3 for 8 h before protein extract preparation. After 
immunoprecipitation with the indicated antibodies, ChIP-enriched DNA was analyzed 
by Q-PCR using the amplicons shown on top. Amplicon number indicates relative 
position to the transcription start site (base pairs). Error bars indicate standard 
deviations over three independent experiments. (B) Nuclear run-on assays 
demonstrate that p21 mRNA is synthesized at similar rates in both HCT116 and 
BV173 cells. (C) mRNA half-life assays indicate that the p21 mRNA half-life is much 
longer in HCT116 cells (~195 min) than in BV173 cells (~43 min). 
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silencing p21 expression, such as translation inhibition or enhanced protein 
degradation, cannot be discarded at this point. 
14-3-3σ  is repressed via promoter DNA methylation 
 Next, Ramiro investigated the mechanism mediating differential expression of 14-
3-3σ. 14-3-3σ is an intronless gene harboring a p53 response element ~1.8 kb 
upstream of the transcription start site (Figure 3.6A). As for p21, ChIP assays detected 
equivalent levels of p53 and increased histone acetylation at the 14-3-3σ regulatory 
region in HCT116 and BV173 cells (Figure 3.6A). However, RNAP II occupancy at the 
proximal promoter is greatly reduced in BV173 cells, suggesting that a repressive event 
downstream of p53 binding and histone acetylation is taking place at the 14-3-3σ locus 
in these cells. It has been reported that 14-3-3σ transcription is silenced in some 
cancers via aberrant DNA methylation of its promoter region (Henrique et al, 2005; 
Kunze et al, 2006). To investigate this possibility, Ramiro performed methylation-
specific PCR assays. Results in Figure 3.6B indicate that the 14-3-3σ promoter is 
indeed  methylated in BV173, LNCaP and SJSA cells (none of which expresses 14-3-
3σ), but is unmethylated in HCT116 cells.  
Differential expression of miR-34a is due to differences in pri-miRNA 
processing 
 While Ramiro worked out the mechanisms driving cell type-specific p21 and 14-
3-3σ expression, I investigated the mechanism behind differential expression of miR-
34a in HCT116 versus BV173 cells. Unlike some miRNAs that are derived from the 
introns present within a protein-coding gene, miR-34a is encoded by its own 
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Figure 3.6 | The 14-3-3σ  promoter DNA is methylated in several cancer cell 
types. (A) ChIP analysis of the 14-3-3σ locus reveals similar binding of p53 and 
histone acetylation in HCT116 and BV173 cells, but absence of RNAP II in the latter. 
(B) Methylation-specific PCR demonstrates that the 14-3-3σ promoter DNA is 
hypermethylated in BV173, LNCaP and SJSA cells. Genomic DNA was analyzed by 
PCR with primer pairs recognizing the alternative methylation states. Reactions were 
analyzed by agarose electrophoresis (top) and Q-PCR (bottom). 
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transcription unit (an intergenic miRNA) containing p53 binding sites within the first exon 
(Figure 3.7A). I performed ChIP analysis and found that Nutlin-3 induces a significant 
increase in both chromatin-bound p53 and histone acetylation at the 5’ end of the miR-
34a locus in both cell types (Figure 3.7A). Although basal levels of total, chromatin-
bound RNAP II are significantly higher in HCT116 cells, Nutlin-3 treatment leads to 
equivalent levels of total, chromatin-bound RNAP II in both cell lines (Figure 3.7A).  
Most importantly, I detected similar levels of S2P-CTD at the 3’ region in Nutlin-3-
treated HCT116 and BV173 cells. These results mimic those obtained for the p21 locus, 
and prompted me to investigate whether differences in miR-34a levels might be due to 
post-transcriptional events. To test this, I designed Q-PCR primer sets to measure total 
pri-miR-34a (both unprocessed and processed, labeled α in Figure 3.7B) or only the 
unprocessed form (labeled β). We also employed TaqMan assays to measure the 
abundance of mature, fully processed miR-34a (γ). Analysis of total pri-miR-34a 
supports the notion that the miR-34a locus is transcriptionally activated in both cell 
types, as BV173 cells accumulate significant amounts of this RNA species upon Nutlin-
3 treatment (Figure 3.7B). Interestingly, although BV173 cells accumulate somewhat 
less total pri-miR-34a than HCT116 cells, they carry significantly more of the 
unprocessed pri-miRNA. This suggests that pri-miRNA processing is impaired in BV173 
cells, and, accordingly, they express much less of the mature form of miR-34a (γ).   
 In summary, I have found that mature miR-34a expression inversely correlates 
with the induction of apoptosis in response to p53 activation following Nutlin-3 
treatment, and my loss-of-function studies in HCT116 cells suggests that miR-34a may 
function in an anti-apoptotic manner in cells treated with Nutlin-3.  Furthermore, my data  
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Figure 3.7 | Unequal pri-miR-34a processing among cancer cell types. (A) ChIP 
analysis demonstrates effective RNAP II activation at the miR-34a locus in both 
HCT116 and BV173 cells. (B) Q-RT-PCR analysis of pri-miR-34a expression reveals 
its reduced processing in BV173 cells. RNA was extracted before and 16 h after 
Nutlin-3 treatment and analyzed by standard Q-RT-PCR with amplicons recognizing 
total pri-miR-34a (α) or unprocessed pri-miR-34a (β). Levels of mature miR-34a were 
analyzed by TaqMan Q-RT-PCR assays (γ). Error bars indicate standard deviations 
over three independent experiments. 
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suggest that in BV173 cells, defective miRNA processing may account for the observed 
decrease in mature miR-34a accumulation in these cells.  
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CHAPTER IV 
DISCUSSION AND PROPOSED FUTURE EXPERIMENTATION 
 
 
PREFACE 
 p53 lies at the center of a vast signaling network, capable of activation by myriad 
upstream stimuli, and once activated, p53 exerts its biological effects predominately by 
regulating the transcription of over one hundred target genes. Once it was established 
that p53 can be activated by a broad number of tumor-promoting stimuli and that p53 
can regulate several distinct cellular responses to these stimuli, I think the field became 
consumed with answering one question: how is cell fate choice determined following 
p53 activation?  In other words, how does p53 ‘connect the dots’ between a given stress 
stimulus and a particular cellular outcome?  In the following sections, I will discuss my 
efforts to elucidate novel molecular mechanisms driving both stimulus- and cell type-
specific responses to p53 activation, doing so in the context of the prevailing dogma.  
Where appropriate, I will propose future experiments designed to extend my published 
findings and will conclude by briefly prognosticating about what the future holds for p53 
research and the design of cancer treatments. 
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STIMULUS-SPECIFIC RESPONSES TO p53 ACTIVATION  
 The question of how diverse p53-activating stimuli elicit different p53-dependent 
cellular responses is undoubtedly an important one.  Attempts to provide a single 
answer this question have produced several models wherein the cellular outcome 
following p53 activation is defined by p53 post-translational modifications and/or p53 
binding proteins (Das et al, 2007; Samuels-Lev et al, 2001; Sykes et al, 2006; Tang et 
al, 2006). I think these models are by their very nature ‘p53-centric,’ in that they make at 
least two large assumptions.  First, they assume that a p53-activating stimulus capable 
of eliciting a cellular response does so by activating p53 exclusively.  Second, they 
assume that the cellular response initiated following p53 activation is strictly p53-
dependent.  As I will discuss below, I believe my data provide sufficient evidence that 
these assumptions are unrealistic, and that current models explaining p53-dependent 
cell fate choice determination are too reductionist to be accurate. 
 My work on stimulus-specific cellular responses upon p53 activation identified 
key regulatory events that seem to reside away from the p53 molecule itself. My results 
can not be explained by any of the previous models proposing that cell fate choice is 
determined by differential transcriptional regulation of cell cycle arrest genes, such as 
p21 and 14-3-3σ, versus the apoptotic genes PUMA and BAX (Figure 2.1). Thus, I 
turned my attention toward other gene modules within the p53 network that might 
influence p53-dependent cell fate choice. This led to the unexpected discovery that a 
key differential event between arresting and apoptotic cells is activation of the extrinsic 
apoptotic pathway downstream of the DR4 and DR5 death receptors, as summarized in 
Figure 4.1. As discussed below, these observations contribute to our understanding of 
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several molecular processes including, but not restricted to, regulation of p53 DNA 
binding and transactivation activities, regulation of the intrinsic and extrinsic apoptotic 
pathways by p53 and modulation of BAX activity by BH3-only proteins. 
The role of DR4 in cell fate choice upon p53 activation 
 First and foremost, p53 is a transcription factor. Naturally, many efforts aimed at 
understanding context-dependent p53 responses have focused on the regulation of its 
DNA binding and transactivation activities. Several studies have indicated that these 
biochemical steps can be regulated by stress-induced p53 post-translational 
modifications and p53 binding proteins. Repeatedly, the p53 target genes reported to be 
affected by these modifications and cofactors are p21, 14-3-3σ, PUMA and BAX. For 
example, the HZF protein was shown to associate with p53 to allow binding and 
transactivation of the p21 and 14-3-3σ promoters while blocking binding to the BAX 
locus (Das et al, 2007). Conversely, the p53-binding protein ASPP2 was shown to 
increase binding to and transactivation of BAX, but not p21 (Samuels-Lev et al, 2001). 
Similarly, acetylation of lysine 120 in the p53 DNA binding domain was shown to 
stimulate transactivation of PUMA, but not p21 (Sykes et al, 2006; Tang et al, 2006). 
However, none of these gene-specific effects seem to play a role in our experimental 
setting, as p21, 14-3-3σ, PUMA and BAX are equally induced by p53 in Nut3- and 5FU-
treated cells. Of note, prior studies have shown equal p21 upregulation in cells that 
undergo cell cycle arrest versus those that undergo apoptosis upon p53 activation (el-
Deiry et al, 1994). In contrast to the prevailing models, my research revealed an 
unprecedented role for the DR4 death receptor in modulating p53-dependent cell fate 
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Figure 4.1 | Stimulus-specific assembly of the p53 circuit in response to p53 
activation by Nutlin-3 versus 5-FU in HCT116 cells. Both Nutlin-3 and 5-FU 
strongly activate genes involved in both cell cycle arrest and apoptosis; however, 
only 5-FU treatment results in p53-independent stabilization of DR4 mRNA and 
concomitant upregulation of DR4 protein levels, which is required for caspase 8 
activation and proteolytic activation of BID into tBID. Activation of the DR4:tBID axis 
by 5-FU drives the apoptotic response by promoting oligomerization of poised BAX at 
the mitochondria. Figure adapted from (Sullivan et al, 2012) 
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choice. I found that DR4 expression is induced in a stimulus-specific manner, and along 
with caspase 8 and BID, is required for BAX activation and p53-dependent apoptosis.   
 My finding that DR4 is required for p53-dependent apoptosis in response to 5FU 
treatment, coupled with the fact that Nut3 treatment induces neither increased DR4 
expression nor apoptosis, provides a novel link between DR4 expression and p53-
dependent apoptosis.  These data also suggest that differential activation of the 
extrinsic apoptotic pathway, via DR4 or perhaps other factors, may be a novel predictor 
of p53-dependent cell fate choice. To the best of my knowledge my work is the first to 
demonstrate that DR4 is required for 5FU-induced apoptosis.  Given that 5FU is still 
highly used in the clinic, particularly in treating colorectal cancers, it is exciting to 
speculate that DR4 may become a new prognostic indicator of a patient’s response to 
5FU treatment. 
 My findings, however, do not demonstrate that Nut3 fails to induce apoptosis 
solely because it fails to induce DR4 expression. One way to investigate this issue is to 
express DR4 at sub-lethal levels in Nut3-treated cells and observe apoptosis.  I have, in 
fact, attempted this experiment using transient transfection of plasmids encoding either 
wild-type DR4 or a DR4 mutant incapable of recruiting the FADD adaptor protein (kind 
gifts of Dr. Andrew Thorburn, UCDHSC).  Unfortunately, duplicate experiments revealed 
that transfection with even the lowest amount of wild-type DR4 plasmid resulted in 
complete killing of the cells, even in the absence of Nut3 treatment (data not shown), 
and I did not pursue this line of experimentation further.  Interestingly, little to no cell 
death was observed in cells transfected with the mutant DR4 plasmid (data not shown), 
suggesting that the death observed in cells overexpressing wild type DR4 is not simply 
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an experimental artifact.  These data are consistent with published reports 
demonstrating that exogenous overexpression of death receptors is sufficient to induce 
apoptosis, even in the absence of the cognate death ligand (Baker & Reddy, 1996; 
Chinnaiyan et al, 1996; Pan et al, 1997).   
 One possible explanation for the failure of Nut3 to induce apoptosis in a majority 
of cancer cell lines is that additional, p53-independent events may be required to 
overcome oncogenic pro-survival signaling. Since 5FU has pleiotropic effects on cellular 
metabolism whereas Nut3 activates p53 very specifically, it is likely that 5FU treatment 
provides both p53-dependent and -independent signals to efficiently induce apoptosis.  
Consistent with this idea, increased expression of DR4 mRNA after 5FU treatment is 
not completely abrogated in HCT116 p53-/- cells (Figure 2.12A), suggesting that full DR4 
induction requires both p53 and additional, unidentified factors.  In fact, my research 
revealed that stimulus-specific induction of DR4 mRNA is not due to a differential ability 
of Nut3 and 5FU to transactivate the DR4 locus, but rather to p53-independent mRNA 
stabilization upon 5FU treatment. Thus, the coordinated action of p53 and other 
complementary stress-activated pathways tips the balance toward the apoptotic 
response in 5FU-treated cells. Unfortunately, almost nothing is known about the 
regulatory factors governing DR4 mRNA turnover, although one study has shown that 
DR4 mRNA levels are increased in cells that lack the RNA binding protein HuR (Ghosh 
et al, 2009).  Interestingly, I found that the NOXA mRNA was also stabilized in a p53-
independent manner upon 5FU treatment, yet the MDM2 mRNA was not affected in this 
way. These observations point to the action of one or more gene-specific regulators of 
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mRNA stability whose activities are likely regulated by genotoxic stress. Future studies 
will be required to identify and characterize these regulators.  
 It is important to note that although I focused my efforts on the role of DR4 in cell 
fate choice, it has been amply demonstrated that DR5 also contributes to the p53 
apoptotic response in cells treated with 5FU and other genotoxic agents. Elegant work 
by the El-Deiry group showed that knockdown of DR5 reduces 5FU-induced cell death 
of HCT116 cells and reduces tumor growth in vivo (Wang & El-Deiry, 2004). In mice, 
which have but one pro-apoptotic TRAIL receptor gene that is transactivated by p53 
(likely a hybrid of DR4 and DR5), gene knockout experiments showed that this pathway 
contributes to p53-dependent, ionizing radiation-induced apoptosis in various tissues 
(Finnberg et al, 2005). Since DR4 and DR5 bind the same ligand, it is not clear if and 
how they have specialized to mediate activation of the extrinsic apoptotic pathway in 
different contexts. In this regard, my work shows that while both receptors are induced 
upon 5FU treatment and required for 5FU-induced apoptosis, DR4 is not activated upon 
non-genotoxic activation of p53 with Nut3, thus revealing important regulatory 
differences between these two genes in human cells. Interestingly, in response to 
ionizing radiation, p53 activation in mice leads to DR4/DR5 induction in tissues that 
undergo apoptosis but not in those that undergo cell cycle arrest (Burns et al, 2001; Fei 
et al, 2002; Finnberg et al, 2005). Thus, differential activation of the extrinsic pathway 
downstream of DR4 and/or DR5 could be a better predictor of the tissue-specific 
responses elicited by p53 activation in human patients, as compared to activation of p21 
or some mitochondrial apoptotic factors, which seem to be activated regardless of 
outcome in various scenarios. 
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The impact of multi-step activation of BAX on cell fate choice 
 Regulation of BAX activity is a critical event in apoptosis. BAX mediates 
permeabilization of the mitochondrial outer membrane for release of pro-apoptotic 
molecules such as cytochrome C and SMAC/DIABLO (Jin & El-Deiry, 2005). Members 
of the BCL2 family of anti-apoptotic factors bind to BAX and prevent its activation (Jin & 
El-Deiry, 2005). Members of the BH3-only family of apoptotic proteins promote BAX 
activity by: 1) binding to BCL2 family members and preventing their interaction with BAX 
(‘derepression/sensitizer’ mechanism), and/or 2) binding to and allosterically activating 
BAX (‘direct activation’ mechanism) (Jin & El-Deiry, 2005). The precise contribution of 
different BH3-only proteins to the ‘derepression’ versus ‘direct activation’ mechanisms is 
currently the subject of intense debate and is under investigation by several groups. 
This debate is clearly illustrated by PUMA, which has been proposed to mediate 
apoptosis by engaging multiple BCL2 family members without binding BAX or BAK 
(Willis et al, 2007), but has also been shown to directly activate BAX by triggering both 
its mitochondrial translocation and oligomerization (Kim et al, 2009). These models are 
not necessarily mutually exclusive and it is possible that PUMA contributes differentially 
to each mechanism in a context-dependent fashion.  
 While there is no doubt that PUMA contributes to p53-dependent apoptosis in 
response to 5FU and other genotoxic agents in HCT116 and other cell types (Chipuk et 
al, 2005; Gomes & Espinosa, 2010; Nakano & Vousden, 2001; Yu et al, 2001), my 
analyses clearly indicate that transactivation of endogenous PUMA by p53 is not 
sufficient to induce apoptosis. In my experimental system, total and mitochondrial levels 
of PUMA protein are identical between arresting and apoptotic cells, revealing a 
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requirement for additional signals to induce cell death.  One possibility is that cells are 
protected from the killing effects of endogenous PUMA by the action of survival factors, 
some of which may be induced by Nut3 itself.  
 Another key observation from our present work is that arresting cells are primed 
for apoptosis by having translocated BAX to the mitochondria, but this form of BAX is 
not fully activated and remains poised in a monomeric state. Importantly, it has been 
shown that BAX is activated in a stepwise fashion, where two distinct biochemical steps 
mediate membrane translocation and oligomerization (Kim et al, 2009). In the simplest 
interpretation, PUMA induction suffices only to induce the first biochemical step in our 
system. Our results indicate that tBID then completes BAX activation at the 
mitochondria by inducing its oligomerization.  Although both PUMA and tBID have been 
considered equally competent to induce both steps of BAX activation in certain cell-free 
assays (Kim et al, 2009), our results are more consistent with a model where PUMA 
and tBID cooperate to induce BAX activation. Functional collaboration between PUMA 
and tBID has been observed in other cell-free assays, where pre-treatment of 
mitochondria with PUMA BH3 domain peptides sensitized them to tBID-induced 
permeabilization by approximately 100-200 fold (Chipuk & Green, 2009). Furthermore, 
overexpression of PUMA is significantly less efficient at inducing apoptosis in bid -/- 
MEFs as compared to wild type cells (Chipuk & Green, 2009). My results reinforce the 
importance of this cooperation in cell fate choice and identify a key biochemical event 
that could be modulated to drive cells into alternative p53 responses. It remains to be 
determined to what degree this cooperation between the intrinsic and extrinsic 
pathways is conserved across diverse cell types. Our finding that the 
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DR4/FADD/caspase 8/tBID pathway defines cell fate choice in both colorectal cancer 
and lung cancer cells suggests that it is not a rare event. Interestingly, the El-Deiry 
group has recently shown that the intrinsic pathway may rely on extrinsic signals in 
more scenarios than previously expected (Kuribayashi et al, 2011). In fact, they found 
that dr4/5 -/- and puma -/- animals do not show additive protection from radiation-induced 
apoptosis in any of the investigated tissues.  
 Taken together, the results discussed above are consistent with a model wherein 
PUMA induction serves to direct BAX to the mitochondria, but that tBID is required to 
drive BAX oligomerization and apoptosis.  If this model is in fact correct, this would be a 
significant contribution to our understanding of how PUMA functions to promote p53-
dependent apoptosis; however, I believe additional experimentation is required to gain 
further insight into how PUMA and tBID collaborate to activate BAX and apoptosis.  
Below, I will highlight some questions that remain unanswered as well as suggest some 
experiments designed to address them. 
What role does PUMA play in stimulus-specific BAX activation and apoptosis? 
 The finding that both total and mitochondrial PUMA levels are the same in Nut3- 
and 5FU-treated cells, coupled with the knowledge that BAX accumulates at the 
mitochondria equally in Nut3- and 5FU-treated cells, suggests that PUMA may be 
sufficient to recruit BAX to the mitochondria.  This hypothesis was in fact tested by a 
post-doctoral fellow in our lab, Dr. Zdenek Andrysik, but yielded conflicting results. In 
one set of experiments, Zdenek isolated mitochondria from wild-type and PUMA-/- 
HCT116 cells treated with vehicle (DMSO), Nut3 or 5FU and chemically crosslinked 
BAX using BMH.  Using this technique, levels of monomeric BAX appear mostly 
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unaffected, while BAX dimerization is significantly reduced by the loss of PUMA (Figure 
4.2A).  Interestingly, when Zdenek measured the levels of total BAX in mitochondria-
enriched fractions that had not been chemically crosslinked, there was a significant 
decrease in the amount of BAX localized to the mitochondria in PUMA-null cells (Figure 
4.2B).  Based on these conflicting results, it remains to be determined whether PUMA 
plays a role in recruiting BAX to the mitochondria in my experimental setting. The 
above-mentioned experiments must be repeated until a clear answer emerges, and we 
should test whether chemical crosslinking has any effect on the outcome of these 
experiments. 
What is the status of monomeric, mitochondrial BAX in Nut3-treated cells? 
 One major conclusion of my paper is that Nut3 treatment facilitates BAX 
translocation to the mitochondria, but not the oligomerization of BAX into pores 
necessary to initiate apoptosis (Figure 2.1C and D).  We suspected that in Nut3-treated 
cells, expression of the BH3-only protein PUMA is sufficient to induce a conformational 
change in BAX that allows it to partially insert into the MOM but remain as a monomer, 
a form we refer to as ‘poised’ BAX.  We further hypothesized that in 5FU-treated cells, 
the action of tBID allows this poised BAX to oligomerize and form pores to trigger 
apoptosis.  While I have shown that BAX is indeed present in a monomeric form at the 
mitochondria of Nut3-treated cells, I am uncertain as to the conformational status of this 
poised BAX.  More specifically, I am interested in whether the mitochondrial BAX in 
Nut3-treated cells is truly inserted into the MOM or is merely peripherally associated 
  89  
 
 
                     
 
 
Figure 4.2 | Analysis of mitochondria-associated BAX protein in wild type, 
shBID and PUMA-/- HCT116 cells.  (A) Mitochondria-enriched fractions were 
prepared from wild-type (+/+), BID-deficient (shBID) and PUMA-null (PUMA-/-) 
HCT116 cells treated with vehicle (DMSO), 10 uM Nutlin-3 (Nut3) or 375 uM 5-
fluorouracil (5FU) for 24 h and subjected to chemical cross-linking with 1,6-
bismaleimidohexane (BMH), which has been previously shown to cross-link BAX 
monomers (Kim et al, 2009).  Following cross-linking, proteins were prepared for 
SDS-PAGE analysis using our standard protocol.  Note that recruitment of 
monomeric BAX to the mitochondria in PUMA-/- cells is not significantly different from 
wild-type cells upon Nut3 treatment, whereas there may be a slight defect in cells 
treated with vehicle or 5FU.  (B) Cells were treated exactly as in A, but mitochondria 
were not subjected to BMH cross-linking.  Note that in this experiment, there is a 
clear defect in BAX recruitment to the mitochondria in PUMA-/- cells under all three 
treatment conditions despite very similar total BAX levels.  Dr. Zdenek Andrysik in 
our laboratory performed all experiments shown in Figure 4.2. 
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with the membrane.  The key experiment to perform in order to discriminate between 
partially inserted and peripherally associated BAX is an alkaline wash.  In this 
technique, isolated, intact mitochondria are subjected to a high-pH wash, stripping away 
all non-integral membrane proteins.  Immunoblot analysis of the partitioning of BAX 
between the wash and membrane fractions would reveal whether the BAX present at 
the mitochondria is inserted into the membrane or not. 
 There is another piece of data that calls into question whether the monomeric 
BAX seen at the mitochondria in Nut3-treated cells is actually inserted into the 
membrane.  Based on a large body of biochemical and biophysical data, it is currently 
believed that in order for BAX to transition from a soluble protein in the cytosol to a 
mitochondria-localized form that it must undergo a major conformation change.  This 
shift in the conformation exposes a C-terminal α-helix targeting BAX for insertion into 
the MOM, as well as the N-terminal 6A7 epitope of BAX, which can be detected by 
immunoprecipitation with the conformation-specific antibody.  Although there is a report 
demonstrating that BAX can reside at the mitochondria with a single α-helix inserted 
into the membrane, I do not see how that is possible without exposing the 6A7 epitope.  
My data show that the 6A7 epitope is not exposed in cells treated with Nut3 (Figure 
2.1E); therefore, this suggests that mitochondrial BAX in Nut3-treated cells is most likely 
not inserted into the membrane but rather is peripherally associated with the MOM.  
Although unlikely, it remains formally possible that in Nut3 treated cells the requisite 
conformation change required for insertion of BAX into the MOM has occurred but that 
the 6A7 epitope is masked somehow, explaining my inability to detect activated BAX in 
Nut3-treated cells. 
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CELL TYPE-SPECIFIC RESPONSES TO p53-ACTIVATION 
 Similar to the notion that different p53-activating stimuli can elicit different cellular 
responses in a single cell type, so too can a single p53-activating stimulus trigger 
different cellular responses depending on the cell type.  And, just as for stimulus-
specific p53-responses, the question of how a given p53-activating agent can cause 
varying outcomes in different cell types is still a matter of intense study.  In the following 
sections, I will discuss data from our lab on cell type-specific responses to the non-
genotoxic p53 activator, Nutlin-3 (Paris et al, 2008), and suggest some experiments to 
gain additional insight into cell-type specific responses to p53 activation.  I should note 
that my specific contribution to this work was the discovery of miR-34a as a p53-
regulated miRNA, characterization of miR-34a expression across different cell types, 
and determination of miR-34a function in HCT116 cells treated with Nutlin-3.  The 
remainder of the work on p21 and 14-3-3σ was carried out by Ramiro París, Sarah 
Stephens and Jennifer Hoover.  Because my studies focused on miR-34a, the majority 
of my discussion will center around the role of miR-34a and other p53-regulated 
miRNAs.  
 In Chapter 3, I presented data demonstrating that upon Nut3 treatment, some 
cancer cell lines undergo reversible cell cycle arrest without apoptosis (e.g. HCT116, 
colorectal cancer; A549, lung cancer), some arrest at first and then commit to apoptosis 
(e.g. SJSA, osteosarcoma; LNCaP, prostate cancer), and one cell type undergoes 
apoptosis without signs of arrest (e.g. BV173, chronic myelogenous leukemia).  
Although p53 and several apoptotic targets were equally activated in all cell lines, we 
observed a clear correlation between the expression of p21, 14-3-3σ and miR-34a and 
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the outcome adopted.  HCT116 and A549 cells expressed high levels of the three arrest 
genes, SJSA and LNCaP cells expressed high levels of p21, mid-levels of miR-34a and 
no 14-3-3σ, and BV173 cells expressed none of these three p53 targets. Mechanistic 
studies showed that the observed differences were due to a combination of cell type-
specific degradation of p21 mRNA, 14-3-3σ promoter DNA methylation and impaired 
processing of the miR-34a primary transcript (Paris et al, 2008). Importantly, we showed 
that attenuation of miR-34a function in HCT116 p21-/- 14-3-3σ-/- cells led to a 
significant increase in apoptosis upon Nutlin-3 treatment relative to HCT116 cells 
expressing all three genes, suggesting that the concerted action of p21, 14-3-3σ and 
miR-34a protects cells from p53-dependent apoptosis.  In summary, these data suggest 
that the expression levels of p21, 14-3-3σ and miR-34a may influence, at least in part, 
cell type-specific cellular responses to p53 activation (Figure 4.3). 
 The findings described above provide a very strong correlation between the 
expression of just three p53-target genes and the fate adopted by a cell treated with 
Nutlin-3. Importantly, these data evoke several important, experimentally tractable 
questions, as discussed below. 
What are the relative contributions of p21, 14-3-3σ  and miR-34a to the 
protection of cells from Nut3-induced apoptosis? 
 Across several cell lines, we have demonstrated a strong correlation between 
p21, 14-3-3σ and miR-34a expression and whether or not a cell undergoes cell cycle 
arrest or apoptosis following p53 activation with Nutlin-3. In the case of HCT116 cells, 
we moved from correlation to causation via genetic deletion of the p21 and 14-3-
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Figure 4.3 | A mechanistic model for cell type-specific p53 responses following 
non-genotoxic p53 activation by Nutlin-3 in two cancer cell lines.  In BV173 cells 
(left), the cell cycle arrest integrated circuit is impaired by p21 mRNA decay, 14-3-3σ 
promoter methylation and impaired processing of miR-34a. In contrast, these three 
cell cycle arrest genes are effectively activated in HCT116 cells (right), where they 
function coordinately to establish a cell cycle arrest response, even though potent 
apoptotic genes such as PUMA have also been induced.  Figure adapted from 
(Sullivan et al, 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
failed signaling
pro-apoptotic signaling
pro-arrest signaling
HCT116BV173
Apoptosis
p53
p21 14-3-3! miR-34a PUMA
mRNA
decay
DNA
methylation
p53
p21 14-3-3! miR-34a PUMA
decreased
miRNA
processing 
p53-dependent transcription
mRNA
decay
p53
p21 14-3-3!DR4 DR5 FAS PUMA BAX
BID
cleavage
tBID
Nutlin-3 Nutlin-3
Nutlin-3
A
B
Cell type-specific configurations
Stimulus-specific configurations
HCT116
mRNA
decay
Cell Cycle Arrest
Cell Cycle Arrest
i
Caspase 8
Activation
Signal
Integrator
p53
p21 14-3-3!DR4 DR5 FAS PUMA BAX
5-FU mRNA
stabilization
Apoptosis
Caspase 8
Activation
Signal
Integrator
BID
cleavage
tBID
BAX
oligomerization
BAX
oligomerization
Signal
Integrator
Signal
Integrator
Sullivan et al, Figure 4
failed signaling
pro-apoptotic signaling
pro-arrest signaling
HCT116BV173
Apoptosis
p53
p21 14-3-3! miR-34a PUMA
mRNA
decay
DNA
methylation
p53
p21 14-3-3! miR-34a PUMA
decreased
miRNA
processing 
p53-dependent transcription
mRNA
decay
p53
p21 14-3-3!DR4 DR5 FAS PUMA BAX
BID
cleavage
tBID
Nutlin-3 Nutlin-3
Nutlin-3
A
B
Cell type-specific configurations
Stimulus-specific configurations
HCT116
mRNA
decay
Cell Cycle Arre t
Cell Cycle Arrest
i
Caspase 8
Activation
Signal
Integrator
p53
p21 14-3-3!DR4 DR5 FAS PUMA BAX
5-FU mRNA
stabilization
Apoptosis
Caspase 8
Activation
Signal
Integrator
BID
cleavage
tBID
BAX
oligomerization
BAX
oligomerization
Signal
Integrator
Signal
Integrator
Sullivan et al, Figure 4
  94  
3σ   genes coupled with miR-34a antagonism, which showed that these three genes do 
indeed influence the cellular response to p53 activation.  In order to extend these 
findings, I would reestablish p21, 14-3-3σ and miR-34a expression in cell lines lacking 
these factors, and conversely, would perform loss-of-function experiments in the cell 
lines that express one or more of these factors.  For example, if re-expression of p21, 
14-3-3σ and mature miR-34a in BV173 cells blocked apoptosis and restored cell cycle 
arrest upon p53 activation with Nutlin-3, this would make a stronger argument for the 
importance of these three factors in determining p53-dependent cell fate choice.  It 
would also be interesting to alter the expression of each factor individually through gain- 
or loss-of-function experiments where appropriate, in A549, SJSA, LNCaP and BV173 
cells in order to determine if any of these factors act in a redundant manner or synergize 
to affect cell fate choice. 
How is pri-miR-34a processing impaired in BV173 cells? 
 Through careful measurement of pri-, pre- and mature miR-34a levels in BV173 
cells coupled with studies of miR-34a transcription, I concluded that BV173 cells 
accumulate less mature miR-34a than HCT116 cells due to impaired processing of the 
primary miR-34a transcript, yet the underlying cause remains elusive.  I should point out 
that other p53-inducible miRNAs, such as miR-205, do not show the same pattern of 
cell type-specific expression as miR34a. In fact, I found that miR-205 is most highly 
expressed in SJSA cells, with the other cell lines showing lower, roughly equivalent 
levels (data not shown).  Furthermore, using microarray technology I measured the 
abundance of several hundred miRNAs in both HCT116 and BV173 cells treated with 
p53 activating agents, and found dozens of miRNAs that were upregulated in each cell 
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type, indicating that BV173 cells have a functional miRNA biogenesis machinery (data 
not shown).  However, I can not discard the notion that BV173 cells may show impaired 
processing of many more miRNAs beyond miR34a. If impaired miR-34a processing 
turns out to be unique amongst the miRNA repertoire in BV173 cells, this might suggest 
a cis-acting defect, such as a mutation in the primary miRNA transcript that hampers 
processing, perhaps by altering the binding of one or more Microprocessor components 
such as Drosha or DGCR8.  Sequencing of the primary miR-34a transcript in HCT116 
and BV173 cells could help rule this possibility out, but as the pri-miR-34a transcript is 
approximately 30 kB long, I would first focus my efforts on sequencing a smaller region 
encompassing the pre-miR34a stem-loop structure.  Additionally, I could perform an 
RNA immunoprecipitation (RIP) experiment to measure association of the primary miR-
34a transcript with known Microprocessor components, as has been previously 
demonstrated for other pri-miRNA transcripts (Suzuki et al, 2009).  Undoubtedly, future 
characterization of miRNA expression across cancer types will reveal aberrant miRNA 
biogenesis, and it will be interesting to see what mechanisms emerge to explain such 
processing defects.  
What is the underlying mechanism driving p21 mRNA destabilization in BV173 
cells?  
 As a direct transcriptional target of p53, it was quite surprising to me when 
Ramiro’s studies revealed that lack of p21 protein expression in BV173 cells was not 
due to transcriptional defects, but was instead due, at least in part, to enhanced p21 
mRNA decay.  Given the prominent role that 3’ untranslated regions (UTRs) play in 
mediating mRNA stability, one hypothesis Ramiro entertained was that a cis-acting 
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mutation in the p21 3’ UTR in BV173 cells might destabilize the mRNA in these cells; 
however, cloning and sequencing of the p21 cDNA from BV173 and HCT116 cells 
revealed no differences in the 3’ UTR sequences (Ramiro París, personal 
communication).  It remains possible, however, that mutations elsewhere in the mRNA 
play a role in its destabilization, or that the up- or down-regulation of one or more trans-
acting factors might destabilize the p21 mRNA in BV173 cells.  In terms of trans-acting 
factors that may influence p21 mRNA stability, a handful of candidate proteins are 
known.    For instance, the RNA binding proteins HuR and AUF1 have been shown to 
stabilize and destabilize the p21 transcript, respectively (Figueroa et al, 2003; Lal et al, 
2004).  Another candidate modulator of p21 mRNA stability is RNPC1 protein, a direct 
p53-target gene that has been shown to stabilize p21 under basal and p53-induced 
conditions (Shu et al, 2006).  To the best of my knowledge, Ramiro never measured the 
levels of these proteins or their association with the p21 transcript in HCT116 versus 
BV173 cells, thus it remains unknown whether one or more of these RNA binding 
proteins mediates p21 mRNA destabilization in BV173 cells. 
 Lastly, it is also possible that defects in mRNA processing, such as capping or 
splicing, or impaired translation of the p21 mRNA might result in its enhanced turnover, 
and these hypotheses have not been thoroughly tested.  Northern blot analysis and Q-
RT-PCR utilizing primer pairs that span intron-exon junctions could be employed to 
detect splicing defects, whereas RIP experiments using anti-7mG antibodies might be 
useful in detecting capping defects.  To investigate impaired translation as a cause of 
enhanced p21 mRNA turnover, the levels of p21 mRNA associated with ribosomes 
could be assayed by means of polysome preparations coupled with either Northern blot 
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or Q-RT-PCR measurements of p21 mRNA levels.  In sum, the mechanism of p21 
mRNA destabilization in BV173 cells remains elusive and awaits further interrogation. 
How does the 14-3-3σ  promoter DNA become methylated?  
 Silencing of tumor suppressor genes via promoter DNA methylation is a frequent 
event during cancer development. The mechanism driving 14-3-3σ promoter 
methylation remains to be elucidated. It has been reported that the protein kinase IKKα 
prevents 14-3-3σ  promoter DNA methylation, as IKKα -/- keratinocytes display 
repressive histone modifications and recruitment of DNA methyltransferases to this 
locus (Zhu et al, 2007). It will be interesting to determine if differential IKKα activity 
contributes to cell type-specific silencing of 14-3-3σ and, consequently, to the apoptotic 
efficacy of Nutlin-3. 
Does miR-34a function solely in a pro-survival/anti-apoptotic manner?   
 Concurrent with my identification of miR-34a as a p53-regulated miRNA (a p53-
miR), several other groups published similar findings on miR-34a, as well as on the 
highly-related miRNAs, miR-34b and miR-34c.  The first studies to be published, using 
both mouse models and human cell lines, identified miR-34a as a direct p53-target gene 
and both found that miR-34a functioned in a pro-apoptotic manner (Chang et al, 2007; 
Raver-Shapira et al, 2007).  Shortly thereafter, another group found miR-34a, miR-34b 
and miR-34c to be direct p53-target genes and that miR-34 overexpression promotes 
cell cycle arrest, not apoptosis (He et al, 2007).  Interestingly, another group also 
claiming miR-34a as a direct p53-target gene found that overexpression of miR-34a 
induced both apoptosis and G1 cell cycle arrest (Tarasov et al, 2007).   
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 Following these original accounts describing the direct regulation of the miR-34a 
family loci by p53, investigation into additional biological roles for the miR-34a family 
increased substantially.  My own work demonstrated that miR-34a inhibition using 
locked nucleic acid (LNA) technology increased apoptosis in HCT116 colon carcinoma 
cells treated with Nutlin-3, suggesting a pro-survival or anti-apoptotic role for miR-34a 
(Paris et al, 2008).  Confirming my finding, blockade of miR-34a function also increases 
apoptosis in human and murine cells in the context of MYC overexpression and 
genotoxic stress, respectively (Bhatt et al, 2010; Sotillo et al, 2011).  miR-34a 
overexpression was found to induce a senescence-like growth arrest in two colon 
cancer lines, both in vitro and in mouse xenograft models, possibly through perturbation 
of the E2F transcription factor pathway (Tazawa et al, 2007).  Another study found miR-
34a expression to be significantly decreased in uveal melanoma cells compared to 
normal melanocytes, and reintroduction of miR-34a in these cells decreased cell 
proliferation and migration through the direct down-regulation of the MET proto-
oncogene (Yan et al, 2009).  miR-34a has also be shown to target MET in glioma and 
medulloblastoma cell lines, and transient expression of miR-34a in glioma cell lines and 
xenografts strongly blocked cell proliferation and growth, respectively (Li et al, 2009).  
Additionally, miR-34a expression is upregulated during oncogene-induced senescence 
and has been shown to directly target the MYC proto-oncogene; interestingly, miR-34a 
expression is p53-independent in this scenario, requiring instead the ELK-1 transcription 
factor for induction (Christoffersen et al, 2010). miR-34a has even been shown to play 
an active role in the differentiation of both normal neural and glioma stem cells (Aranha 
et al, 2011; de Antonellis et al, 2011; Guessous et al, 2010).  Related to these roles in 
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stem cell differentiation, the miR-34 family has recently been shown to cooperate in 
inhibiting the generation of induced pluripotent stem cells (iPSC), a process known to be 
hindered by p53 (Choi et al, 2011).  
 In addition to the miR-34 family, a handful of new p53-miRs have been 
discovered, such as miR-605, which has been described as a direct p53-target gene 
that targets MDM2, thereby potentiating p53 activation (Xiao et al, 2011).  The Prives 
lab recently discovered a novel p53-target locus, the PVT-1 non-coding RNA, which 
generates several miRNAs.  Amongst these, miR-1204 induces cell death when 
overexpressed in cells in a partially p53-dependent fashion (Barsotti et al, 2011).  In 
most cases, however, there is no solid evidence that these novel p53-miRs are directly 
regulated by p53 at the transcriptional level.  For example, microarray and Q-RT-PCR 
measurements revealed that miR-192 and miR-215 expression is upregulated by p53 
and results in increased p21 expression and cell cycle arrest (Braun et al, 2008; 
Georges et al, 2008).   
 In summary, the miR-34 family of miRNAs were the first p53-regulated miRNAs 
to be discovered and remain the most well-studied of all the p53-inducible miRNAs.  It is 
interesting, though not surprising, that so many different cellular roles have been 
ascribed to the miR-34a family depending on the experimental context.  The miR-34a 
family can induce cell cycle arrest, apoptosis, senescence, differentiation and can inhibit 
cell migration.  How might so many outcomes be controlled by just three miRNAs?  I 
think the answer, though complicated, lies in the combinatorial control of gene 
expression.  For example, miRNAs often have several target mRNAs in any given cell 
type, and any given mRNA is often controlled by more than one miRNA.  Therefore, the 
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specific mRNA and miRNA expression patterns in a cell will likely determine the final 
outcome of modulating the expression of a single miRNA or miRNA family.  Additionally, 
because a particular miRNA and its direct target mRNAs function in the context of 
thousands of other proteins and RNAs, the ultimate cellular response following 
perturbation of a single miRNA is undoubtedly dependent on global gene expression 
and signaling.  I predict that future studies of miRNA function will mirror those of miR-
34a, wherein multiple functions are ascribed to a miRNA depending on the cellular 
context.  Until computational techniques catch up with our ability to generate large 
datasets, I think it will be difficult to predict the outcome of modulating a single miRNA in 
any one experimental setting.  Perhaps the answer is that there does not need to be 
one answer.  If any one concept has been reinforced in me during my dissertation 
research, it is that macromolecules function within the context of an ever-changing 
milieu of other macromolecules.  As such, reliably predicting how a cell will respond to 
modulation of a single protein or RNA across a range of conditions is difficult if not 
impossible at present.  
 
FINAL REMARKS 
 For quite some time, I have been at odds with the p53-centric mentality of the 
p53 field.  Although I think the atmosphere is beginning to change, the idea that p53-
dependent stress responses are decided in a p53-autonomous fashion is still pervasive 
in the literature.  Despite being a relative newcomer to the study of p53, my dissertation 
work leads me to believe that a unifying model to explain p53 function may not exist, 
and clinically speaking, I am not convinced that such a universal model would be of any 
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use.  Based on both my published and unpublished results, I conclude in this chapter 
that p53-independent events are critical determinants of the cell fate choice following 
p53 activation.   
 An important, perhaps obvious, implication of this conclusion is that in order to 
make significant strides in the treatment of human tumors and cancers, we should 
abandon p53-centric notions.  Rather, we must obtain a comprehensive understanding 
of the molecular signaling pathways that are activated and repressed across a library of 
stimuli, and we must do so across an equally diverse collection of both tumor and 
healthy cell types.  Only when we fully understand what other molecular events occur 
concomitantly with p53 activation in the context of specific stresses and cell types, and 
importantly, how the p53 pathway interacts with these other pathways, will we be able to 
effectively treat tumors and cancers with greater efficacy and fewer off-target effects.   
 I predict that the future of p53 research will be based largely on clever genetic 
screens designed to elucidate novel signaling pathways, proteins and even non-coding 
RNAs that influence p53 function.  Furthermore, such genetic screens could be used to 
identify efficacious treatment regimens that would not be otherwise predicted based on 
our current knowledge.  In addition to the increased use of genetic screens, I also 
foresee a need for more in vivo studies using tumor explant and xenograft models to 
understand how the tumor microenvironment influences the response to p53-based 
treatments.  Regardless of what the future holds for the study of p53, I sincerely hope 
that some of my findings will be of use to the research community at large, perhaps 
even impacting how future patients are treated in the clinic. 
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MATERIALS AND METHODS 
 
Cell culture 
Cells were grown in McCoy’s 5A (HCT116), DMEM (RKO) or RPMI1640 (H460, BV173) 
medium supplemented with 10% FBS (Sigma-Aldrich) and antibiotic/antimycotic mix 
(Invitrogen) at 37°C/5.0% CO2. Unless otherwise noted, DMSO vehicle control (Sigma-
Aldrich), Nutlin-3R (Nut3, Cayman Chemical) and 5-fluorouracil (5FU, Sigma-Aldrich) 
were used at 0.1%, 10.0 µM and 375.0 µM, respectively.  Doxorubicin (Sigma-Aldrich), 
Camptothecin (Sigma-Aldrich) and Etoposide (Sigma-Aldrich) were used at 0.5 µM, 2.0 
µM and 1.0 µg/mL, respectively. For UVC irradiation of HCT116 cells, media was 
aspirated from the plate prior to treatment with UVC (50J/m2) in a UV Stratalinker® 2400  
(Stratagene). Media was then replaced and the cells incubated at 37°C/5.0% CO2 for 24 
h prior to harvesting for Western blot analysis.  
 
Quantitative-Reverse Transcriptase-PCR (Q-RT-PCR) 
RNA extractions, cDNA synthesis and Q-RT-PCR were performed as previously 
described (Gomes et al, 2006).  Briefly, total RNA was isolated using an RNeasy kit 
(Qiagen) and first-strand cDNA was synthesized using the qScript kit (Quanta 
Biosciences) according to the manufacturer’s instructions. cDNA was analyzed by Q-
RT-PCR Absolute Quantification method (SYBR green, ABI) on an ABI 7900HT 
instrument. Primer sequences are listed in Tables 4.2 and 4.6. 
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Western blots and antibodies 
Protein preparation, quantification and immunoblot analyses were performed as 
previously described (Gomes et al, 2006).  Antibody information is supplied in Tables 
4.1 and 4.5. 
 
BAX 6A7 Immunoprecipitation 
Immunoprecipitation of activated BAX protein was performed as described (Kim et al, 
2009) with minor modifications. Cells were treated with DMSO, Nut3, or 5FU for 24 h, 
washed once in PBS, resuspended in 1.0% CHAPS Buffer (1.0% (w/v) CHAPS, 142.5 
mM KCl, 2.0 mM CaCl2, 20.0 mM Tris–Cl, pH 7.4) and dounce homogenized. Lysates 
were cleared by centrifugation (21,000 g for 20 min at 4°C). In all, 1.0 mg of protein 
extract was pre-cleared with Protein-G sepharose beads (GE Healthcare) for 1.5 h at 
4°C and incubated with 5.0 mg of mouse 6A7 antibody (Trevigen) overnight at 4°C. IPs 
were washed with 1.0% CHAPS buffer, eluted by boiling in 1X SDS–PAGE loading dye, 
and subjected to immunoblot analysis.  
 
Mitochondria isolation and BAX protein crosslinking  
Subcellular fractionation was performed as described in Pallotti and Lenaz (2007).  
Cells were washed with cold 1X PBS, resuspended in swelling buffer (10.0 mM Tris–
HCl pH 7.5, 10.0 mM NaCl, 1.5 mM MgCl2), and incubated on ice for five minutes. Cell 
suspensions were adjusted to 0.25 M sucrose and dounce homogenized. Undisrupted 
cells and large cellular fragments were pelleted by centrifugation at 1,000 g. 
Mitochondria in the supernatant were separated from the cytosolic fraction by 
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centrifugation at 10,000 g and loaded onto a 1.0–1.7 M discontinuous sucrose gradient. 
Mitochondria were then recovered from the interphase. Isolated mitochondria were 
either directly lysed in SDS buffer (1.0% SDS, 10.0% glycerol, 100.0 mM Tris, pH 7.4) 
or first crosslinked with bismaleimidohexane (Pierce) using the manufacturer’s protocol 
prior to lysis. Samples were then analysed by immunoblot. 
 
Quantification of cell surface death receptor levels  
HCT116 cells were treated for 24 h, trypsinized, and resuspended in 1.0% BSA 
(Fraction V) in 1X PBS. In all, 1x105 cells were labeled with the appropriate antibody or 
isotype control for 1.0 h at 25°C, washed with 1% BSA/PBS, and stained with 
secondary antibody for 1.0 h at 25°C in the dark. Flow cytometry was carried out as 
described above. MFIs were calculated as the ratio between the mean fluorescence 
value of the specific antibody and that of the appropriate isotype control. Histograms 
were created using the FlowJo Software package (Tree Star, Inc.). Antibodies used for 
detection are listed in Table 4.1. 
 
mRNA half-life determination 
Cells were treated with DMSO, Nut3 or 5FU for 12 h, followed by the addition of 10.0 
µg/mL Actinomycin D (ActD, Sigma-Aldrich) to the culture medium. Total RNA was 
isolated at several time points after the addition of ActD, reverse-transcribed and 
subjected to Q-RT-PCR analysis as described above. 
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Chromatin Immunoprecipitation (ChIP) analyses 
HCT116 cultures were grown to 50%-60% confluency and treated with 0.1% (v/v) 
DMSO (Sigma-Aldrich), 10.0 µM Nutlin-3R (Cayman Chemical) or 375.0 µM 5-
fluorouracil (Sigma-Aldrich).  After PBS wash, cells were cross-linked with a 1% 
formaldehyde/PBS solution for 15 minutes at room temperature. Cross-linking was 
stopped by addition of glycine to 125.0 mM final concentration. Cells were washed twice 
with cold 1X PBS and harvested in RIPA buffer (150 mM NaCl, 1% Igepal CA-630, 
0.5% deoxycholate, 0.1% SDS, 50 mM Tris-HCl at pH 8, 5 mM EDTA, 20 mM NaF, 0.2 
mM sodium orthovanadate, 5 µM trichostatin A, 5 mM sodium butyrate, and protease 
inhibitors). Samples were sonicated to generate DNA fragments <500 bp. For 
immunoprecipitation, 1.0 mg of protein extract was pre-cleared for 2 h with 30.0 µL of 
50% Protein G-Sepharose slurry before addition of indicated antibodies. Antibodies 
used are listed in Table 4.1 and 4.5. Between two and five µg of each antibody was 
added to the samples and incubated overnight at 4°C in the presence of 30.0 µL of 
Protein G-beads pre-blocked with 1.0 mg/mL BSA and 0.3 mg/mL salmon sperm DNA. 
When antibodies against phosphorylated forms of the RNAPII CTD were used, 
immunocomplexes were recovered using anti-mouse IgM/protein G-Sepharose beads 
(Sigma-Aldrich). Beads were washed twice with RIPA buffer, four times with ChIP Wash 
Buffer (100 mM Tris-HCl at pH 8.5, 500 mM LiCl, 1% [v/v] Nonidet P-40, 1% [w/v] 
deoxycholic acid), twice again with RIPA buffer, and twice with 1X TE buffer. 
Immunocomplexes were eluted for 10 min at 65°C with 1% SDS, and cross-linking was 
reversed by adjusting to 200 mM NaCl and incubating five h at 65°C. DNA was purified, 
and a fraction was used as template in real-time PCR reactions. Primers against 
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multiple regions of the p21 locus were designed with Primer Express 2.0 (Applied 
Biosystems; see Tables 4.4 and 4.8 for ChIP Q-PCR primer sequences). Real-time 
PCR products range in size between 50 and 75 bp. 10 µL real-time PCR reactions 
containing 1X SYBR Green Mix (Applied Biosystems), 1% of the total ChIP-enriched 
DNA recovered, and 100.0 nM primers were set up in 384-well plates using an 
Eppendorf epMotion 5070 robot. Standard curves from 1-200 ng of sonicated genomic 
DNA were run alongside ChIP samples for each individual amplicon, and plates were 
read in an Applied Biosystems 7900HT Real-time PCR instrument (Absolute 
Quantification Method). Normal serum and input DNA values were used to 
subtract/normalize the values from ChIP samples. 
 
Flow cytometric determination of cell cycle profiles and apoptotic indices 
For cell cycle distribution profiles, cells were harvested by trypsinization, washed twice 
with cold PBS, and resuspended in PBS/2mM EDTA. Cells were then fixed overnight in 
50% ethanol. Before cell sorting, cells were washed in PBS/2 mM EDTA, treated with 
RNase A, and stained with 50 µg/ml propidium iodide. For apoptotic index assays, cells 
were harvested by trypsinization, washed with PBS, and resuspended in Annexin V 
Binding Buffer [10 mM Hepes pH 7.4, 140 mM NaCl, 2.5 mM CaCl2]. Cells were then 
stained with Annexin V-fluorescein conjugate (Invitrogen) and propidium iodide, 
following manufacturer’s instructions. Cells were analyzed on either a Cyan Analyzer 
(Dako) for data shown in Chapter 2 or a FACScan instrument (Beckton-Dickinson) for 
data shown in Chapter 3. 
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shRNA-mediated knockdown 
shRNAs were designed using the PSICOLIGOMAKER 1.5 software, freely available 
from the Jacks Lab website (http://web.mit.edu/jacks-lab/protocols/pSico.html), and 
cloned into the pLL3.7 expression vector.  Commercially available shRNAs pre-cloned 
into the pLKO.1-Puro vector (shCTRL and shDR4) were purchased from Sigma-Aldrich. 
Oligonucleotide sequences for all shRNAs used in Chapter 2 are listed in Table 4.3. 
Lentiviral particles were produced in HEK293FT packaging cells. HCT116, RKO and 
H460 cells were transduced with 0.45 µm-filtered viral supernatants. Selection of stably 
transduced cells was carried out for 2-7 days with either 100.0 µg/mL G418 or 10.0 
µg/mL puromycin (Sigma-Aldrich). 
 
Nuclear Run-on assays 
Cell cultures were treated with 10 µM Nutlin-3 (Cayman Biochemicals) or left untreated 
for 8 h before nuclei isolation as described previously (Bjorge et al, 1989). Nuclei were 
resuspended in 100 µl of Reaction Buffer (Bjorge et al, 1989) and incubated at 30°C for 
15 min. Labeled RNA was isolated and hybridized to nitrocellulose filters onto which the 
p21 cDNA had been blotted. Filters were washed as described and analyzed by 
PhosphoImager. 
 
Methylation-specific PCR 
Genomic DNA was isolated and modified by sodium bisulfite treatment as previously 
described (Herman et al, 1996).  Methylation-specific PCR analysis was done using 
alternative primer sets covering CpG dinucleotides in the 14-3-3σ promoter region 
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(Table 4.7) and 50 ng of bisulfite-treated gDNA. For gel electrophoresis analysis, PCR 
reactions were stopped at 37 cycles and run on EtBr-stained agarose gels. For Q-PCR 
quantification, reactions were run along standard curves with known amounts of PCR 
products obtained from either HCT116 cells (unmethylated) or LNCaP cells 
(methylated) and analyzed by SYBR green incorporation. 
 
Analysis of miR-34a expression 
Levels of mature miR-34a were measured using Taqman MicroRNA Assays (Applied 
Biosystems). Small RNAs were purified using the miRVana miRNA Isolation Kit 
(Ambion). Expression was normalized to that of U6 snRNA. Levels of total and 
unprocessed pri-miR-34a were measured by standard Q-RT-PCR using primer pairs 
against sequences in Exon 1 and around Drosha cleavage sites in Exon 2, respectively, 
and normalized to 18S rRNA. 
 
Knock-down of miR-34a activity 
miR-34a activity was inhibited in cultures of HCT116 p21-/- 14-3-3σ-/- cells using a 
specific Anti-miR™ oligonucleotide (Ambion) targeting mature miR-34a. Control or anti-
miR-34a oligonucleotides were transfected with siPORT™ NeoFX™ transfection 
reagent (Ambion) following manufacturer’s instructions.  Media was replenished at 24 h 
post-transfection +/- 10.0 µM Nutlin-3 and cells were harvested 96 h later for apoptotic 
index assays.  
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Table 4.1 | Antibodies used in Chapter 2.  Abbreviations: western blot 
(WB),immunoprecipitation (IP), flow cytometry (FC), secondary antibody (2° Ab), goat 
anti-mouse (GAM), donkey anti-rabbit (DAR), donkey anti-mouse (DAM), RNA 
polymerase II (RNAP II), Santa Cruz Biotechnology (SCB), Cell Signaling Technology 
(CST), BD Transduction Labs (BD). 
 
 
 
 
 
 
 
 
 
 
 
Protein/Epitope Use Manufacturer Catalog  
Number 
14-3-3! WB SCB sc-7683 
Actin WB SCB sc-1616-R 
BAX WB CST 2772 
BAX (6A7 epitope)  IP Trevigen 2281-MC-100 
BCL2 WB CST 2872 
Bcl-XL WB CST 2762 
BID/tBID WB CST 2002 
Caspase 3 (Asp175)  WB CST 9661 
Caspase 8 WB CST 9746 
Caspase 9 WB CST 9502 
COX4 WB SCB sc-69359 
Cytochrome C WB CST 4272 
DR5 WB/FC ProSci Inc. 2019 
DR4 WB ProSci Inc. 1139 
DR4  FC R&D Systems MAB347 
FADD WB SCB sc-56093 
FAS (clone CH11) FC Millipore  05-201 
FAS WB SCB sc-8009 
NOXA  WB Abcam Inc. ab13654 
Nucleolin WB SCB sc-8031 
p21   WB SCB sc-817 
p53 (pantropic) WB Calbiochem  OP43 
PARP WB Enzo Life Sci. BML-SA250 
PUMA WB SCB sc-28226 
TRADD WB BD  610572 
"-tubulin WB Sigma-Aldrich T9026 
normal rabbit IgG serum FC SCB sc-3888 
normal mouse IgG serum FC SCB sc-2025 
GAM IgG-HRP  WB (2° Ab) SCB sc-2005 
DAR IgG-HRP  WB (2° Ab) SCB sc-2317 
Alexa Fluor 488® DAR IgG FC Invitrogen A21206 
Alexa Fluor 488® DAM IgG FC Invitrogen A21202 
RNAP II (clone H14) ChIP Covance MMS-134R 
RNAP II (clone H5) ChIP  Covance MMS-129R 
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Table 4.2 | Q-RT-PCR primer sequences used in Chapter 2.  Primer sequences read 
5’-3’ from left to right.  Where appropriate, official gene symbols are noted in 
parentheses. 
 
 
 
 
 
 
 
Table 4.3 | Oligonucleotide sequences for shRNAs used in Chapter 2.  *shCTRL is 
a non-targeting shRNA purchased from Sigma-Aldrich (catalog number- SHC002). 
shDR4 and shDR5 were also purchased from Sigma-Aldrich [TRC numbers- 
TRCN0000005934 (DR4) and TRCN0000005933 (DR5) ].  All other shRNA constructs 
were designed in-house and cloned into the pLL3.7 expression vector.  
  
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table II: Q-RT-PCR Primer Sequences 
 
 
 
 
 
 
 
 
Gene Name Forward Primer Sequence  Reverse Primer Sequence  
   
18S rRNA 
(RN18S1) 
GCCGCTAGAGGTGAAATTCTTG CTTTCGCTCTGGTCCGTCTT 
BID TACGCACCTACGTGAGGAGCT CTGTCCGTTCAGTCCATCCC 
DR5 
(TNFRSF10B) 
TGTCGCCGCGGTCCT TGGGTGATCAGAGCAGACTCAG 
DR4 
(TNFRSF10A) 
TTGCTTGCCTCCCATGTACAG CAGGGACTTCTCTCTTCTTCA 
FAS GGGCATCTGGACCCTCCTAC GATAATCTAGCAACAGACGTAAGAACCA 
MDM2 GGCGATTGGAGGGTAGACCT CACATTTGCCTGGATCAGCA 
NOXA 
(PMAIP1) 
GCAAGAACGCTCAACCGAG CAAATCTCCTGAGTTGAGTAGCACAC 
p21 
(CDKN1A) 
CTGGAGACTCTCAGGGTCGAAA GATTAGGGCTTCCTCTTGGAGAA 
 
 
 
 
 
 
 
 
 
Where appropriate, official gene symbols are noted in parentheses. 
 
Supplementary Table III: Oligonucleotide sequences for shRNA cloning 
 
 
 
shRNA Name  shRNA oligonucleotide sequences (5’ to 3’) 
  
shNOXA  For: TGGATGAGAGAACATTATAATTCAAGAGATTATAATGTTCTCTCATCCTTTTTTC 
Rev: TCGAGAAAAAAGGATGAGAGAACATTATAATCTCTTGAATTATAATGTTCTCTCATCCA 
shCasp8 For: TGAGCTGCTCTTCCGAATTATTCAAGAGATAATTCGGAAGAGCAGCTCTTTTTTC 
Rev: TCGAGAAAAAAGAGCTGCTCTTCCGAATTATCTCTTGAATAATTCGGAAGAGCAGCTCA 
shBID For: TGAAGACATCATCCGGAATATTCAAGAGATATTCCGGATGATGTCTTCTTTTTTC 
Rev: TCGAGAAAAAAGAAGACATCATCCGGAATATCTCTTGAATATTCCGGATGATGTCTTCA 
shFADD For: TGCAGTCCTCTTATTCCTAATTCAAGAGATTAGGAATAAGAGGACTGCTTTTTTC 
Rev: TCGAGAAAAAAGCAGTCCTCTTATTCCTAATCTCTTGAATTAGGAATAAGAGGACTGCA 
shTRADD For: TGTTAAGCAATGATAATAAATTCAAGAGATTTATTATCATTGCTTAACTTTTTTC 
Rev: TCGAGAAAAAAGTTAAGCAATGATAATAAATCTCTTGAATTTATTATCATTGCTTAACA 
shFAS For: TGACACTAAGTCAAGTTAAATTCAAGAGATTTAACTTGACTTAGTGTCTTTTTTC 
Rev: TCGAGAAAAAAGACACTAAGTCAAGTTAAATCTCTTGAATTTAACTTGACTTAGTGTCA 
shCTRL* CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT 
shDR4* CCGGCTTAGGTGTTAGGAGTTAATACTCGAGTATTAACTCCTAACACCTAAGTTTTT 
shDR5* CCGGGCAGAAGATTGAGGACCACTTCTCGAGAAGTGGTCCTCAATCTTCTGCTTTTT 
 
* shCTRL is a non-targeting shRNA purchased from Sigma-Aldrich (catalog number- SHC002). shDR4 and shDR5 were also 
purchased from Sigma-Aldrich [TRC numbers- TRCN0000005934 (DR4) and TRCN0000005933 (DR5) ].  All other shRNA 
constructs were designed in-house and cloned into the pLL3.7 expression vector. 
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Table 4.4 | ChIP Q-PCR Primer Sequences used in Chapter 2.  Amplicon names 
refer to the position of the center of the amplicon generated by the indicated primer 
set.  By convention, the transcription start site (TSS) of each gene is assigned 
position ‘+1’. Positions downstream (3’) of  the TSS are denoted as (+); positions 
upstream (5’) of the TSS are denoted as (-). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table IV: ChIP Q-PCR Primer Sequences 
 
 
CDNK1A (p21) locus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TNFRSF10A (DR4) locus  
 
 
 
 
 
 
 
 
 
 
 
 
 
Amplicon names refer to the position of the center of the amplicon generated by the indicated primer set.  By  
convention, the transcription start site (TSS) of each gene is assigned position ‘+1’. Positions downstream (3’) of  
the TSS are denoted as (+); positions upstream (5’) of the TSS are denoted as (-). 
 
Q-PCR Amplicon 
Name 
Forward Primer Sequence (5’-3’) Reverse Primer Sequence (5’-3’) 
   
-2965 CCGGCCAGTATATATTTTTAATTGAGA AGTGGTTAGTAATTTTCAGTTTGCTCAT 
-2283 AGCAGGCTGTGGCTCTGATT CAAAATAGCCACCAGCCTCTTCT 
-1391 CTGTCCTCCCCGAGGTCA ACATCTCAGGCTGCTCAGAGTCT 
-20 AGCTGCGCCAGCTGAGG CACAAGGAACTGACTTCGGCA 
+507 CCAGGAAGGGCGAGGAAA GGGACCGATCCTAGACGAACTT 
+4001 AGTCACTCAGCCCTGGAGTCAA GGAGAGTGAGTTTGCCCATGA 
+8655 CCTCCCACAATGCTGAATATACAG AGTCACTAAGAATCATTTATTGAGCACC 
+11443 TCTGTCTCGGCAGCTGACAT ACCACAAAAGATCAAGGTGAGTGA 
Q-PCR Amplicon 
Name 
Forward Primer Sequence (5’-3’) Forward Primer Sequence (5’-3’) 
   
-2019 TCCTATCCAGGGCAATTCAGCAACA TCCTATTGTCAGTAACCAAAAACTGTCTCAGT 
-929 CTCCTCAGCCCCAAGGTCGC TCACGGTCCTGCCTGCGAAG 
-28 AAGCTGAGAGCGGCAAGGGC CCTGCGGCTCCTGTTGGCTA 
+543 TCACTTGTGGCGGGGCATGT GGGACCCCGTTCTTCCTCCG 
+12990 TGCCAGTCCCTGCTTTGTCCC TGGACACAACTCTCCCAAAGGGC 
+23142 CCCGAGTGTGCTGGTGCAGA CCCCAACTCCCTCCCCCTCA 
+33307 AGCTGGTACAGCAGGCCCAG CAGGGTGTGGATCGAGGCGT 
+34681 GGGCAGTGGGCAGCTCTCAT ACCAAATCTTTGCATAGGTACCAAATAACACATTT 
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Table 4.5 | Antibodies used in Chapter 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
 
 Supplementary Table 1. Antibody information. 
 
Protein/Epitope Source Catalog Number 
p53 Oncogene Science OP43, DO1 clone  
14-3-3!  Santa Cruz Biotechnology, Inc. sc-7683 
p21 Santa Cruz Biotechnology, Inc. sc-817 
PUMA (Ab-1) Calbiochem PC686 
Nucleolin (C23) Santa Cruz Biotechnology, Inc. sc-8031 
Actin Santa Cruz Biotechnology, Inc. sc-1616 
Acetyl-Histone H4 Upstate 06-866 
RNA polymerase II Santa Cruz Biotechnology, Inc. sc-9001 
S5P-CTD Covance MMS-134R 
S2P-CTD Covance MMS-129R 
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Table 4.6 | Q-RT-PCR primer sequences used in Chapter 3. Primer sequences 
read 5’-3’ from left to right. 
 
 
 
 
 
Table 4.7 | Q-PCR Primer sequences used for analysis of 14-3-3σ promoter DNA 
methylation in Chapter 3.  Primer sequences read 5’-3’ from left to right. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2
 
Supplementary Table 2. Oligonucleotide sequences for Q-RT-PCR analysis of gene expression. 
 
Gene 
(Genbank ID) 
Forward Primer Reverse Primer 
p21 
(NM_078467) 
CTGGAGACTCTCAGGGTCGAAA GATTAGGGCTTCCTCTTGGAGAA 
PUMA 
(NM_014417) 
TCAACGCACAGTACGAGCG AAGGGCAGGAGTCCCATGAT 
14-3-3-!  
(NM_006142) 
GCCGAACGCTATGAGGACAT CTTCTCCACGGCGCCTT 
PIG3 
(NM_00481) 
AAATTCACCAAAGGTGCTGGAGT TCCGCCTATGCAGTCTAGAATAAGA 
miR-34a Exon1 
(!) (EF592573) 
CTCGGTGACCACGCAGATC GCAGGACTCCCGCAAAATC 
miR-34a Exon2  
(") (EF592573) 
ACTGCCCTAGAAGTGCTGCAC CGCTTCATCTTCCCTCTTGG 
GADD45a 
(NM_001924) 
GGTGTACGAAGCGGCCAA GCAGGCACAACACCACGTTA 
Btg2 
(NM_006763) 
GCGCTCCAGGAGGCACT GGACGGCTTTTCGGGAA 
Hdm2 
(AF527840) 
GGCGATTGGAGGGTAGACCT CACATTTGCCTGGATCAGCA 
Fas/APO 
(NM_152877) 
GGGCATCTGGACCCTCCTAC GATAATCTAGCAACAGACGTAAGAACCA 
18 S 
(NR_003286) 
GCCGCTAGAGGTGAAATTCTTG CTTTCGCTCTGGTCCGTCTT 
 
 4
 
Supplementary Table 4. Oligonucleotide sequences for methylation analysis of 14-3-3! 
promoter. 
 
14-3-3!  
CpG Status 
Forward Primer Reverse Primer 
Methylated TGGTAGTTTTTATGAAAGGCGTC CCTCTAACCGCCCACCACG 
Unmethylated GGTAGTTTTTATGAAAGGTGTT CTCTAACCACCCACCACA 
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Table 4.8 | ChIP Q-PCR Primer Sequences used in Chapter 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3
 
Supplementary Table 3. Oligonucleotide sequences for ChIP analysis. 
 
Locus 
Amplicon 
Forward Primer Reverse Primer 
p21 
 -2965 
CCGGCCAGTATATATTTTTAATTGAGA AGTGGTTAGTAATTTTCAGTTTGCTCAT 
p21 
-2283 
AGCAGGCTGTGGCTCTGATT CAAAATAGCCACCAGCCTCTTCT 
p21 
-1391 
CTGTCCTCCCCGAGGTCA ACATCTCAGGCTGCTCAGAGTCT 
p21 
-20 
TATATCAGGGCCGCGCTG GGCTCCACAAGGAACTGACTTC 
p21 
+507 
CCAGGAAGGGCGAGGAAA GGGACCGATCCTAGACGAACTT 
p21 
+4001 
AGTCACTCAGCCCTGGAGTCAA GGAGAGTGAGTTTGCCCATGA 
p21 
+8566 
CCTCCCACAATGCTGAATATACAG AGTCACTAAGAATCATTTATTGAGCACC 
p21 
+11443 
TCTGTCTCGGCAGCTGACAT ACCACAAAAGATCAAGGTGAGTGA 
14-3-3!  
-1881 
AAACCCTGTAGCATTAGCCCAGA TCTCTTTGCCACAAGGAGGAGTA 
14-3-3!  
-13 
CCAAGAGCAGGAGAGACACAGA GGCTAACTGCTGCCTGGGA 
miR-34a 
-1979 
CAACATGGTGAAACCCCGTC CCCACCACTATGCCCAACTAA 
miR-34a 
+98 
CCCACCTGGTCCTCTTTCCT GACGGGACAGCGGCATC 
miR-34a 
+280 
CTCGGTGACCACGCAGATC GCAGGACTCCCGCAAAATC 
miR-34a 
+30717 
ACTGCCCTAGAAGTGCTGCAC CGCTTCATCTTCCCTCTTGG 
miR-34a 
+31121 
GACCAGGTTTTGAACGCGAG GTGGTTGGGCGCAGATTCT 
miR-34a 
+33099 
GATTGCGCCACTGTATTCCA TTGAGACAGGGTCTGGCTCTG 
 
The amplicon name indicates the position of the central base pair of the amplicon relative to the 
transcription start site of the gene (base pairs). 
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